



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GLOTZER *et al.*

Appl. No. 09/881,736

Filed: June 18, 2001

For: **Cyk-4 Polypeptides, DNA
Molecules Encoding Them and
Their Use in Screening Methods**

Confirmation No. 8755

Art Unit: 1653

Examiner: *To Be Assigned*

Atty. Docket: 0652.2260001/EKS/AES

**Submission of Certified Copy of 35 U.S.C. § 119(a)-(d)
Priority Document In Utility Application**

Commissioner for Patents
Washington, D.C. 20231

Sir:


Submitted herewith are certified copies of Applicants' U.S.C. § 119(a)-(d) priority documents, to perfect the claim to priority filed on June 18, 2001.

Country	Priority Document Appl. No.	Filing Date
Europe	00 112 880.0	June 19, 2000
Europe	01 110 554.1	April 30, 2001

Prompt acknowledgment of this submission is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

for 
Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

Date: December 21, 2001

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

P:\USERS\Ann\Angela\0652\0652.2260001\submit.prioriry.doc

SKGF 8/23/01 mac

2-11-





Europäisches
Patentamt




Bescheinigung

European
Patent Office

Certificate

Office européen
des brevets



Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

00112880.0



Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN
THE HAGUE, 24/04/01
LA HAYE, LE





Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldung Nr.:
Application no.:
Demande n°: 00112880.0

Anmeldetag:
Date of filing:
Date de dépôt: 19/06/00 ✓

Anmelder:
Applicant(s):
Demandeur(s):
Boehringer Ingelheim International GmbH
55218 Ingelheim am Rhein
GERMANY

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:

Cyk-4 polypeptides, DNA molecules encoding them and their use in screening methods

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:
State:
Pays:

Tag:
Date:
Date:

Aktenzeichen:
File no.
Numéro de dépôt:

Internationale Patentklassifikation:
International Patent classification:
Classification internationale des brevets:

C12N15/12, C07K14/47, A01K67/033, C12N15/00

Am Anmeldetag benannte Vertragsstaaten:
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE/UK ✓
Etats contractants désignés lors du dépôt:

Bemerkungen:
Remarks:
Remarques:

19-06-2000

EP00112880.0

DESC

EPO - Munich
31

19. Juni 2000

Case 14/057 DI Fa/dc

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

55216 Ingelheim am Rhein (BRD)

Cyk-4 polypeptides, DNA molecules encoding them and
their use in screening methods

The present invention relates to a new protein Cyk-4, which is involved in cytokinesis, and to therapies interfering with cell division, in particular tumor therapy.

- 5 The process of cytokinesis produces two daughter cells from a single parental cell and permanently segregates the products of the cell division cycle. Cytokinesis is one of the few processes in biology known to require coordination between microtubules and actin filaments.
- 10 Indeed, in animal cells there are two steps in cytokinesis that rely on interactions between microtubules and the actin-based contractile ring (for review see (Field et al., 1999; Glotzer, 1997). In the first instance, the microtubule-based mitotic spindle
- 15 specifies the position of the contractile ring. This allows the division plane to be positioned so that the separated chromosomes are partitioned equally into the two daughter cells. Subsequently, after ingression of the cleavage furrow, there is a second step that
- 20 depends on both microtubules and the contractile ring. Completion of cytokinesis requires the central spindle, which contains bundled, antiparallel microtubules. The molecular mechanisms underlying these two microtubule dependent steps in cytokinesis are not known.
- 25 The degree to which the progression of cytokinesis depends on the central spindle varies somewhat in different experimental organisms. In invertebrate embryos, a transient interaction between astral microtubules of the mitotic spindle and the cell cortex
- 30 is sufficient to position the cleavage furrow

(Rappaport, 1985). Furrows specified in this manner ingress, but if the spindle is removed, these furrows do not usually complete cytokinesis (Rappaport, 1985). In contrast, in *Drosophila* spermatocytes, contractile ring formation requires the central spindle (Giansanti et al., 1998). Similarly, in cultured mammalian cells, astral microtubules appear to be insufficient to induce furrow ingression, instead the presence or absence of a central spindle determines whether or not a cleavage furrow forms (Cao and Wang, 1996; Eckley et al., 1997; Rieder et al., 1997; Savoian et al., 1999; Wheatley and Wang, 1996). Moreover, in cultured cells, the central spindle is also required for completion of cytokinesis (Wheatley and Wang, 1996). In *C. elegans* embryos, as in invertebrate embryos, only the later stages of cytokinesis appear to depend on the central spindle. Embryos depleted of the kinesin-like protein ZEN-4/CeMKlp1 fail to assemble the central spindle, yet cleavage furrows form and ingress, but cytokinesis does not proceed to completion (Powers et al., 1998; Raich et al., 1998). In summary, the initiation of cytokinesis depends on the central spindle in some but not in all organisms, whereas there appears to be a general requirement for the central spindle for the completion of cytokinesis in animal cells. While it is clear that the central spindle plays an important role in cytokinesis the underlying mechanism remains elusive.

Cleavage furrow ingression is driven by the actin-based contractile ring. Like many actin-based structures, the contractile ring requires the RhoA GTPase for its assembly. Rho family GTPases are thought to act as

molecular switches that cycle between inactive GDP-bound forms and active GTP-bound forms; their ability to exchange and hydrolyze GTP is regulated by additional factors, the so-called guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Inactivation of RhoA by the exoenzyme C3 (Aktories and Hall, 1989), inhibits cytokinesis in a wide variety of experimental settings by causing disassembly of cortical actin structures and the contractile ring (Drechsel et al., 1997; Kishi et al., 1993; Mabuchi et al., 1993; Moorman et al., 1996; O'Connell et al., 1999). Further, a Rho GEF is essential for cytokinesis (Prokopenko et al., 1999; Tatsumoto et al., 1999). GTP-bound RhoA interacts with a number of putative effectors including formins, Rho Kinase, Citron kinase, and a regulatory subunit of myosin phosphatase (for review see (Van Aelst and D'Souza-Schorey, 1997). The requirement for RhoA in cytokinesis may reflect its ability to regulate formins since members of the formin gene family are required for cytokinesis in budding yeast (BNI1/BNR1) (Imamura et al., 1997), fission yeast (Cdc12) (Chang et al., 1997), *Drosophila* (*dia*) (Castrillon and Wasserman, 1994) and *C. elegans* (*cyk-1*) (Swan et al., 1998). Several formins also bind to profilin (Chang et al., 1997 ; Evangelista et al., 1997; Imamura et al., 1997; Watanabe et al., 1997), a key regulator of actin polymerization. It is conceivable that GTP-bound RhoA promotes contractile ring assembly by activating actin polymerization via the formins and by activating myosin motor activity.

There is compelling evidence that the microtubule-based central spindle and the actin-based cleavage furrow are both essential for cytokinesis. Next, the question was asked how these two cytoskeletal polymers interact.

5 There are a few cases in which an interaction between the microtubule and actin cytoskeletal systems have been characterized. Examples include nuclear positioning in budding yeast (Carminati and Stearns, 1997; Fujiwara et al., 1999; Miller et al., 1999),
10 spindle orientation in epithelial cells (Busson et al., 1998) and in certain asymmetrically dividing cells, such as the posterior blastomere of the two cell *C. elegans* embryo (Gönczy et al., 1999a; Hyman and White, 1987; Skop and White, 1998; Waddle et al., 1994). In
15 these examples there is evidence that the dynein/dynactin microtubule motor complex may mediate the interaction of microtubules with the cell cortex.

It was an object of the invention to elucidate the microtubule dependent steps in cytokinesis. In
20 particular, it was sought to define the role of the central spindle in this process, in order to be able to interfere with this process and thus with cytokinesis, which provides a new approach for therapy, in particular cancer therapy.

25 Therefore, to solve the problem underlying the invention, it was investigated how the central spindle assembles and how it functions in cytokinesis.

In the course of the experiments, a novel gene, designated *cyk-4*, gene has been identified by genetic
30 analysis in *C. elegans*. Embryos from *cyk-4(t1689ts)*

mutant hermaphrodites were shown to initiate, but to fail to complete, cytokinesis. These embryos also fail to assemble the central spindle. It was shown that the *cyk-4* gene encodes a GTPase activating protein (GAP) for Rho family of GTPases. The Cyk-4 GAP domain activates GTP hydrolysis by RhoA, Rac1 and Cdc42 *in vitro*. RNA-mediated interference of RhoA, Rac1 and Cdc42 suggests that Rho plays an essential role in cytokinesis and is the target of Cyk-4 GAP activity for cytokinesis. It could be shown that Cyk-4 and a Cyk-4:GFP fusion protein localize to the central spindle and persist at cell division remnants. It was found that Cyk-4 localization is dependent on the kinesin-like protein Zen-4/CeMKlp1 and vice-versa. The data obtained in the present invention suggest that Cyk-4 and Zen-4/CeMKlp1 cooperate in central spindle assembly. Central spindle localization of Cyk-4 could accelerate GTP hydrolysis by RhoA thereby allowing contractile ring disassembly and completion of cytokinesis.

In the present invention, the role of the *cyk-4* gene in the early divisions of the *C. elegans* embryo was characterized. It was shown that Cyk-4 is required for the late stages of cytokinesis. Interestingly, *cyk-4* mutant embryos fail to assemble the central spindle. Positional cloning and localization studies revealed that the *cyk-4* gene encodes a novel GTPase activating protein (GAP) for the Rho family of GTPases that localizes to the central spindle. The missense mutation in the *cyk-4(t1689ts)* allele is found in a domain dispensable for GAP activity suggesting that Cyk-4 may have another function in addition to

activating GTP hydrolysis by Rho family proteins. Accordingly, it was found that Cyk-4 and the kinesin-like protein Zen-4/CeMKlp1 are interdependent for their proper localization. Based on these data, a model is
5 proposed by which Cyk-4 acts in concert with Zen-4/CeMKlp1 to assemble the central spindle. The concentration of Cyk-4 to the central spindle would then serve to target the GAP domain to the fully
10 ingressed contractile ring where it could promote GTP hydrolysis by RhoA, thereby facilitating the completion of cytokinesis.

The division of a cell into two daughters requires dynamic interactions between the microtubule-based mitotic spindle and the actin-based contractile ring.
15 In animal cells the position of the cleavage furrow, an actomyosin-based structure, is determined by the mitotic spindle in a manner that is poorly understood. In recent years it has become clear that the central spindle, an array of microtubule bundles that forms
20 during anaphase, also plays an important role in cytokinesis. To gain insight into this fundamental cellular process, the cytokinesis-defective mutant, *cyk-4*, was analyzed. Cytological analysis reveals that *cyk-4* mutant embryos fail to assemble the central
25 spindle. Though lacking a central spindle, *cyk-4* mutant embryos furrow extensively, but they fail to complete cytokinesis. The mutation responsible for the *cyk-4* phenotype was found to be a missense mutation in a gene encoding a Rho family GAP that, *in vitro*,
30 stimulates GTP hydrolysis by Rho, Rac, and Cdc42. CYK-4 localizes to the central spindle and to cell division remnants. CYK-4 colocalizes with the ZEN-4/CeMKLP1

kinesin-like protein. Moreover, CYK-4 and ZEN-4/CeMKLP1 are interdependent for their localization. It is concluded that the CYK-4 GAP and the ZEN-4/CeMKLP1 kinesin-like protein cooperate to assemble the central
5 spindle. Furthermore, it is proposed that a concentrated source of CYK-4 GAP on the central spindle could downregulate the RhoA GTPase and thereby promote the late stages of cytokinesis.

10 The findings of the present invention provide a model for CYK-4 dependent assembly of the central spindle:

In *cyk-4* mutant embryos the robust microtubule bundles that constitute the central spindle do not form. Instead, the spindle develops into two mitotic asters
15 separated by a few overlapping, disorganized, microtubules. A similar phenotype is observed in *zen-4* mutant embryos (Powers et al., 1998; Raich et al., 1998). Thus both the ZEN-4/CeMKLP1 kinesin-like protein and the CYK-4 GAP are essential for this microtubule
20 bundling. The *Drosophila* orthologue of ZEN-4/CeMKLP1 is also required for cytokinesis, though it seems to be required for all aspects of furrow ingression (Adams et al., 1998). Members of the MKLP1 subfamily of kinesin-like proteins have microtubule bundling activity *in*
25 *vitro* (Kuriyama et al., 1994; Nislow et al., 1992). However, *in vivo*, ZEN-4 mediated microtubule bundling requires CYK-4.

In answering the question how CYK-4 and ZEN-4 could cooperate to assemble the central spindle, it is
30 proposed that a complex containing multiple motor

proteins could specifically localize to overlapping, antiparallel microtubules (figure 10). If such a motor complex transits along a microtubule it might continue to an end and dissociate. However, if such a motor
5 complex transited along a microtubule in the vicinity of an antiparallel microtubule, the complex might bind simultaneously to both microtubules and attempt to move alternately in opposite directions, the net result being that the complex would concentrate in the region
10 of microtubule overlap. Since CYK-4 does not have a microtubule motor domain, yet it is essential for the formation of the central spindle, it is proposed that CYK-4 forms a complex with multiple ZEN-4 homodimers that localizes to and stabilizes overlapping
15 antiparallel microtubules (figure 10).

It was of interest to find out if the RhoGAP activity of CYK-4 necessary to promote microtubule bundling by ZEN-4. It is proposed that central spindle assembly is unlikely to require CYK-4 GAP activity. This is
20 suggested by two lines of evidence. First, central spindle assembly is defective in the *cyk-4(t1689ts)* allele that carries a missense mutation at amino acid 15. This substitution is distant from the C-terminal GAP domain, and *in vitro*, the amino terminus
25 of CYK-4 is dispensable for GAP activity. Thus this allele would be predicted to retain catalytic activity *in vivo* and therefore GAP activity is not sufficient for central spindle assembly. Moreover, Rho RNAi experiments reveal that central spindle assembly is Rho
30 independent, suggesting that Rho GAP activity is not required for this process. Thus CYK-4 may act to

promote central spindle assembly, independent of its GAP activity.

In the present invention, the function of the CYK-4 gap domain was analysed:

- 5 If CYK-4 function in central spindle assembly is independent of the Rho GTPase, it was of interest to determine the function of the CYK-4 GAP domain. CYK-4 is likely bifunctional, one function being to promote the assembly of the central spindle, the second
- 10 function being to promote GTP hydrolysis by Rho family members. These two functions might be related in that the first function would serve to concentrate CYK-4 at a site where GAP activity is required. It may be assumed that CYK-4 GAP activity is required late in
- 15 cytokinesis, to promote GTP hydrolysis by a Rho family GTPase whose downregulation causes disassembly of the contractile ring and cell separation (figure 10).

- It was determined which GTPase might CYK-4 act on to promote cytokinesis. The CYK-4 GAP domain has all the
- 20 hallmarks of a Rho family GAP and it may therefore be expected that it will act on this subfamily of the GTPase superfamily. Like many other RhoGAPs, the GAP domain of CYK-4 is promiscuous in its ability to promote GTP hydrolysis on Rho, Rac, and Cdc42 (Lamarche
- 25 and Hall, 1994). The strongest piece of evidence that CYK-4 acts on Rho is based on the observation that of the GTPases tested, Rho is the only one that is clearly essential for cytokinesis. The requirement for Rho in cell division is well documented in a variety of
- 30 experimental systems. To date there is no evidence that

Rac is required for cytokinesis and our data using RNAi to deplete Rac also failed to detect a role for this GTPase in this process. Moreover, it has been recently reported that *ced-10* mutants, which are defective in corpse engulfment subsequent to apoptosis and distal tip cell migration, contain mutations in the *rac* gene (Reddien and Horvitz, 2000). *ced-10* mutants do not have any gross phenotypes indicative of a role in cytokinesis. Moreover, *Rac1* deficient mice are gastrulation defective, but the embryos do not contain multinucleate cells indicative of a cell division defect (Sugihara et al., 1998). The sum of these data argue that Rac is not an essential target of CYK-4 during cytokinesis. With regard to Cdc42, previous studies have implicated this GTPase in cytokinesis (Drechsel et al., 1997; Dutartre et al., 1996). Superficially, the weakly penetrant cytokinesis phenotype observed in *Cdc42(RNAi)* embryos is consistent with these earlier data. However the *Cdc42(RNAi)* embryos that are cytokinesis defective are also osmotically swollen and therefore cytokinesis defect may be indirect. Thus at this juncture it appears most likely that RhoA is the key substrate for the CYK-4 GAP activity.

Further support for the hypothesis that completion of cytokinesis requires downregulation of RhoA by CYK-4 would be supported by experiments in which the *cyk-4* phenotype is phenocopied by RhoA mutants that are hydrolysis defective. However the genetic tools necessary to express such dominant mutants in the early *C. elegans* embryo are currently unavailable. It is surprising that the CYK-4 GAP domain is less active

towards RhoA as compared to Rac or Cdc42, if indeed RhoA is the relevant target of its GAP activity. One possible explanation is that full length CYK-4 has a different activity profile as compared to the isolated
5 GAP domain. A more interesting possibility is that CYK-4 localization is important for CYK-4 GAP activity. The phenotype of *cyk-4* mutant embryos suggests that CYK-4 needs to act when the contractile ring is in close proximity to the central spindle. Since CYK-4 is
10 concentrated on the central spindle at this time, its high local concentration might overcome its lower activity towards RhoA.

In the present invention, the central spindle was shown to be at the center of cytokinesis:

15 There appear to be at least two microtubule-dependent steps in cytokinesis, contractile ring positioning and completion of cytokinesis. In some cells both processes are dependent on the central spindle. An important open question is whether these two reactions
20 are mechanistically similar. While assembly of the contractile ring requires activation of RhoA, it was previously shown that the position of the contractile ring is specified in a RhoA-independent manner in *Xenopus* embryos (Drechsel et al., 1997). It has been
25 shown here that a Rho GAP is required for the late stages of cytokinesis, suggesting that the second process, completion of cytokinesis, does involve RhoA. It is therefore assumed that the two microtubule-dependent steps in cytokinesis are distinct.

CYK-4 and ZEN-4 are not the only components of the central spindle, a number of other components, some of which are required for cytokinesis, are also present at this site. Polo kinase is known to associate with MKLP1
5 and to concentrate in the central spindle (Adams et al., 1998; Lee et al., 1995), and this kinase is essential for cytokinesis. Rho associated kinase also localizes to this site (Kosako et al., 1999). The AIR-2 aurora-like kinase localizes to the central spindle
10 (Schumacher et al., 1998). This kinase seems to be required primarily for chromosome segregation (Woollard and Hodgkin, 1999), its direct involvement in cytokinesis requires further analysis. INCENP and the TD-60 antigen also localize to the central spindle and
15 there is evidence that they may play a role in cytokinesis (Eckley et al., 1997; Mackay et al., 1998; Martineau-Thuillier et al., 1998; Savoian et al., 1999). Interestingly, a Rho GEF that is required for cytokinesis, ECT2, also accumulates on the central
20 spindle (Tatsumoto et al., 1999), however the *Drosophila* ortholog, Pebble, does not localize in this manner (Prokopenko et al., 1999).

Further analysis of the specific functions of all of these cytokinesis regulators is the basis to determine
25 which of these proteins are functionally interdependent as has been shown is the case for Cyk-4 and Zen-4/CeMKlp1.

In summary, the experiments of the present invention comprise an initial phenotypic, molecular, biochemical,
30 and cell biological analysis of the *cyk-4* gene. These studies indicate that this protein is an active GTPase

activating protein that is required for cytokinesis, likely by its ability to regulate the RhoA GTPase. Quite surprisingly, one additional function of this protein is to promote assembly of the central spindle.

5 Cyk-4 is a key molecule required for cytokinesis that regulates both the structure of the late mitotic spindle and the function of the contractile ring.

Thus, the present invention generally relates to Cyk-4 proteins, which have been shown to be essential for

10 this second microtubule dependent step and thus defines a functional link between the central spindle and the contractile ring.

In a preferred embodiment, the invention relates to a mammalian Cyk-4 polypeptide, in particular murine and

15 human Cyk-4.

In a first aspect, the invention relates to the murine Cyk-4 polypeptide with the amino acid sequence as set forth in SEQ ID NO:4 or with the amino acid sequence encoded by a polynucleotide which hybridizes under

20 stringent conditions to a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO:3.

In a preferred aspect, the invention relates to the human Cyk-4 polypeptide with the amino acid sequence as set forth in SEQ ID NO:2 or with the amino acid

25 sequence encoded by a polynucleotide which hybridizes under stringent conditions to a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO:1.

In a further aspect, the present invention relates to an isolated DNA molecule comprising a polynucleotide

with the nucleotide sequence as set forth in SEQ ID NO:1 encoding human Cyk-4 polypeptide, or an isolated DNA molecule encoding human Cyk-4 polypeptide comprising a polynucleotide which hybridizes under
5 stringent conditions to a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO:1.

In a further aspect, the present invention relates to an isolated DNA molecule comprising a polynucleotide with the nucleotide sequence as set forth in SEQ ID
10 NO:3 encoding murine Cyk-4 polypeptide, or an isolated DNA molecule encoding murine Cyk-4 polypeptide comprising a polynucleotide which hybridizes under stringent conditions to a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO:3.

15 By "stringent hybridization conditions" as used herein is meant overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (1X SSC = 150 mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate,
20 and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C, or equivalent conditions.

In the following, if not otherwise stated, the term "Cyk-4" refers to both the murine and the human Cyk-4.

25 Homologues of the subject Cyk-4 proteins also include versions of the polypeptide which are resistant to post-translation modification or which alter the activity of the protein. The Cyk-4 polypeptide can comprise a full length protein, such as represented in SEQ ID NO:2 or 4,
30 or it can comprise a fragment or variant thereof.

Beside DNA molecules, the present invention relates to nucleic acid molecules in the form of RNA, such as mRNA. The DNA molecules include cDNA and genomic DNA obtained by cloning or produced synthetically. The DNA
5 may be double-stranded or single-stranded.

Single-stranded DNA or RNA may be the coding strand, also known as the sense (or plus) strand, or it may be the non-coding strand, also referred to as the antisense (or minus) strand. The present invention also
10 relates to preparations of double stranded Cyk-4 RNA or derivatives thereof that can be used to interfere with gene expression by ds-RNA mediated gene interference as described by Fire et al. 1998 and reviewed by Fire,
1999; Boshier and Labouesse, 2000; Sharp, 1999.

15 By "isolated" nucleic acid molecule(s) is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. Recombinant DNA molecules contained in a vector are considered isolated for the purposes of the present invention. Further
20 examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells, and those DNA molecules purified (partially or substantially) from a solution whether produced by recombinant DNA or synthetic chemistry techniques.

25 Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the DNA molecules of the present invention. However, it is intended that "isolated" as used herein does not include the Cyk-4 cDNA present in a cDNA library or in a preparation of purified or
30 isolated genomic DNA containing the Cyk-4 gene or a portion thereof in admixture with one or more other cDNA molecules or DNA fragments.

The nucleic acid molecules of the present invention further include genetic constructs comprising one or more Cyk-4 DNA sequences operably linked to regulatory DNA sequences (which may be heterologous regulatory sequences), such as promoters or enhancers as described below, wherein upon expression of these DNA sequences in host cells, preferably in bacterial, fungal (including yeast), plant or animal (including insect or mammalian) cells, one or more Cyk-4 polypeptides are produced. In such constructs, the regulatory sequences may be operably linked to a Cyk-4 polynucleotide encoding mature Cyk-4 polypeptide or any of its variants, precursors, fragments or derivatives described herein, which may include one or more polynucleotides having a nucleic acid sequence that is complementary to substantially all or a portion of a nucleic acid molecule having a nucleic acid sequence as shown in SEQ ID NO:1 or 3. As used herein, the terms "a portion" or "a fragment" of a nucleic acid molecule or a polypeptide means a segment of a polynucleotide or a polypeptide comprising at least 15, and more preferably at least 20, contiguous nucleotides or amino acids of a reference polynucleotide or polypeptide (for example, the polynucleotide and polypeptide shown in SEQ ID NOs: 1, or 3, respectively, unless otherwise specifically defined below.)

Besides the DNA molecules having a nucleotide sequence corresponding to that depicted SEQ ID NO:1 or 3, the invention also relates to DNA molecules which comprise a sequence substantially different from those described above but which, due to the degeneracy of the genetic code, still encode the Cyk-4 mouse or human

polypeptides. Since the genetic code is well known in the art, it is routine for one of ordinary skill in the art to produce the degenerate variants described above without undue experimentation.

- 5 In addition, the invention relates to Cyk-4 polypeptides which have deviations from the sequence shown in SEQ ID NO:2 or 4, caused by the conservative exchange of amino acids, if they are Cyk-4 derivatives or fragments or peptides with the properties which are
10 desirable for their use in therapy or in screening assays, or isolated DNA molecules encoding such derivatives or fragments with a polynucleotide sequence varying in their sequence from SEQ ID NO:1 or 3.
- 15 Nucleic acid molecules of the present invention which encode a Cyk-4 polypeptide or a derivative or fragment thereof may include, but are not limited to, those encoding the amino acid sequence of the polypeptide by itself, together with additional, non-coding sequences,
20 including for example introns and non-coding 5' and 3' sequences, such as the transcribed, untranslated regions (UTRs) or other 5' flanking sequences that may play a role in transcription (e.g., via providing ribosome- or transcription factor-binding sites), mRNA
25 processing (e.g. splicing and polyadenylation signals) and stability of mRNA; the coding sequence for the Cyk-4 polypeptide operably linked to a regulatory DNA sequence, particularly a heterologous regulatory DNA sequence such as a promoter or enhancer; and the coding
30 sequence for the Cyk-4 polypeptide linked to one or more coding sequences which code for amino acids that

provide additional functionalities. Thus, the sequence encoding the polypeptide may be fused to a marker sequence, such as a sequence encoding a peptide which facilitates purification of the fused polypeptide. In certain embodiments of this aspect of the invention, the marker amino acid sequence may be a hexa-histidine peptide, such as the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are commercially available. As described for instance in Gentz et al., 1989, hexa-histidine provides for convenient purification of the fusion protein. The "HA" tag is another peptide useful for purification which corresponds to an epitope derived from the influenza hemagglutinin protein, which has been described by Wilson et al., 1984. Yet another useful marker peptide for facilitation of purification of Cyk-4 is glutathione S-transferase (GST) encoded by the pGEX fusion vector (see, e.g., Winnacker, From Genes to Clones, New York: VCH Publishers, pp. 451-481 (1987)). As discussed below, other such fusion proteins include the Cyk-4 fused to immunoglobulin Fc at the N- or C-terminus.

A still further aspect of the present invention relates to antibodies and antibody preparations specifically reactive with an epitope of the Cyk-4 polypeptide.

Polyclonal antibodies are conventionally obtained by immunising animals, particularly rabbits, by injecting the antigen or fragments thereof and subsequently purifying the immunoglobulin.

Monoclonal anti-Cyk-4-antibodies may be obtained by standard procedures following the principle described by Köhler and Milstein, 1975, by immunising animals, particularly mice, then immortalising antibody-producing cells from the immunised animals, e.g. by fusion with myeloma cells, and screening the supernatant of the hybridomas obtained by immunological standard assays for monoclonal anti- Cyk-4 -antibodies. For therapeutic or diagnostic use in humans, these animal antibodies may optionally be chimerised in the conventional way (Neuberger et al., 1984, Boulianne et al., 1984) or humanised (Riechmann et al., 1988, Graziano et al., 1995).

Cyk-4specific antibodies can be used for both diagnostic and screening applications.

Cyk-4 specific antibodies are useful in clinical situations, where determining overexpression or underexpression of CYK-4 has predictive value. Anti-CYK-4 antibodies can be used on tissue of cell specimens to evaluate the level of expression or changes in the subcellular localization in various disease states. In addition anti-CYK-4 antibodies can be used to detect the presence of CYK-4 in solid-phase binding assays as described in the subsequent subsection related to finding compounds that affect the interaction of CYK-4 with other proteins.

In a further aspect the present invention provides methods for identifying compounds capable of modulating, in particular inhibiting cytokinesis by

modulating, in particular inhibiting, the function of CYK-4 to promote GTP hydrolysis by Rho family GTPases.

This aspect of the invention is based on the finding that CYK-4 promotes GTP hydrolysis by Rho family

5 GTPases. Due to the evolutionary conservation of the GTPase domain and the requirement for Rho in cytokinesis, it can be concluded that the ability of CYK-4 to promote GTP hydrolysis by Rho is crucial for CYK-4 function.

10 The assay may be conducted on the basis of the so-called "GTP hydrolysis assay", which is a biochemical assay carried out according to standard protocols, as described, *inter alia*, by Self et al., 1995, or by
15 Settleman and Foster, 1995. By way of example, this assay may be carried out as follows: In a first step, the substrate is incubated with GTP that carries a radioactive label (e.g. the commercially available γ -³²P-GTP or an otherwise measurable, e.g. a fluorescent
20 label, as described, *inter alia*, by Hazlett et al., 1993, under conditions and for a period of time sufficient to allow saturation of GTP binding sites. Subsequently, CYK-4 is added, optionally at various concentrations of from 0 to eg 1 uM; in the presence of
25 absence of test compounds. After the appropriate time (e.g. 5 min.) the amount of GTP that has been hydrolysed is determined.

Compounds that specifically affect the rate of CYK-4-dependent GTP hydrolysis by Rho are drug candidates which may be further developed, e.g. in a first step,
30 by structure-function analysis.

The assay of the invention may be performed in the high throughput format by automation of the reaction steps. In this case, a great number of compounds, e.g. from compound or natural product libraries, are applied to microtiter plates containing the reagents for the binding reaction. After the time required for GTP saturation in the control reaction (absence of test compound), the reaction solution may be filtered through a protein binding matrix, e.g. nitrocellulose, that is arranged in the same geometrical pattern as the original microtiter plate where the reaction took place, and the radioactivity retained in the filters, or the amount of liberated free phosphate (or other label as appropriate) is quantified.

To simplify the assay, the Rho protein may be immobilized on a solid matrix, either via a tag that allows for binding to a suitably modified solid support, e.g. by using a biotinylated Rho protein and a streptavidin-coated microtiter plate, the solid matrix may also be in the form of beads. In the above-described assays that measure GTP hydrolysis, the Rho protein is preferably human.

By way of example, the screening assay may be conducted as follows: A member of the Rho family GTPases is immobilized on a solid support, e.g. a SPA (proximity scintillation assay bead) using either an epitope tag such as His6 or other similar tags. The Rho protein is loaded with radioactive ^{32}P -gamma-GTP in the presence of EDTA. Magnesium is added and the amount of label retained on the beads is measured by scintillation counting. Cyk-4 is added in the absence or presence of

test compounds, incubated for various times at which point the amount of radioactivity or other suitable label remaining associated with the beads measured.

Other embodiments of the assay include using
5 alternative labels such as fluorescent GTP or other radioisotopes and using alternative measures of GTP hydrolysis such as measuring the amount of free ³²P released, as described above.

Alternatively to using the full-length Rho protein, a
10 truncated version may be used, as long the GTPase activity is maintained, e.g. a fragment that lacks the critical cysteine residue in the CaaX box at the C-terminus that is required for membrane targetting.

A number of Rho proteins are available that are
15 suitable for use in a GTP hydrolysis assay as a substrate, they have been cloned from various species. Preferably, they are employed as recombinant proteins.

Examples for Rho substrates that may be employed are human RhoA (Swiss Prot Primary Accession Number
20 P06749), human RhoB (Swiss Prot Primary Accession Number P01121), human RhoC (Swiss Prot Primary Accession Number P08134), human RAC1 (Swiss Prot Primary Accession Number P15154), human RAC2 (Swiss Prot Primary Accession Number P15153), human RAC3
25 (Swiss Prot Primary Accession Number O14658) and human GB25 (Swiss Prot Primary Accession Number P21181).

An example for a co-factor which may be present in the assay reaction is polo kinase, e.g. the murine (Acc. No. NP 035251) or the human (Acc. No. NP 005021)
30 polo-like kinase homolog.

Based on the sequence information, the Rho substrates and the potentially present co-factor(s) can be produced recombinantly in suitable host cells, e.g. in E. coli or by means of baculovirus in insect cells, according to standard methods.

Compounds that have the ability to prevent CYK-4 stimulated GTP hydrolysis by Rho family GTPases are then tested for specificity in a similar assay format using other proteins that have Rho family GAP domains, e.g. p190 or RhoGAP (Lamarche and Hall, 1994).

According to another aspect, the screening method of the invention is based on the biochemical interaction of CYK-4 and members of the MKLP1 subfamily of the kinesin-like protein superfamily.

The function of CYK-4 in cytokinesis is intimately tied to its ability to interact with MKLP1, a kinesin like protein that is also required for central spindle assembly. Therefore compounds that inhibit this interaction are expected to prevent cytokinesis and to inhibit cell proliferation. In C.elegans extracts, CYK-4 and CeMKLP1 are present in a protein complex and can be co-immunoprecipitated. The nature of this protein interaction can be further characterized, in particular by determining whether the interaction is direct or whether it requires additional proteins. In addition, the protein domains required for this interaction can be mapped. Examples for members of the MKLP1 family are CeM03D4.1b (GenBank ID U61955, Protein ID 1397342) and HsMKLP1 (GenBank ID X67155; SwissProt Q02241).

The domains required for the interaction of Cyk-4 and MKLP1 can be identified using recombinant protein fragments of Cyk-4 and MKLP1. For example, agarose beads loaded with GST fusion proteins of Cyk-4 (or
5 another fusion partner, e.g. maltose binding protein, etc.) are incubated with full-length or truncated fragments of MKLP1, the beads are sedimented and the ability of fragments of Cyk-4 to interact with MKLP1, or fragments thereof, are assessed by SDS-page.
10 Alternatively, MKLP1 fragments can be immobilized and assessed for their ability to interact with full length Cyk-4 or fragments thereof. Alternatively, the yeast two hybrid assay can be used to measure the interaction of Cyk-4 protein fragments and MKLP1 protein fragments
15 using standard techniques.

A minimal set of proteins necessary to form a stable complex, i.e. Cyk-4, MLKP1, and potentially additional protein co-factors are produced in recombinant form and a screening assay is conducted, preferably in the high
20 throughput format, that measures the ability of test compounds to inhibit this interaction. Additional factors that may be required for the interaction can be identified in a biochemical complementation assay or a two hybrid assay. Since it is known that polo kinase
25 forms a complex with Cyk-4, this protein is one of the potential co-factors required for the interaction with Cyk-4. In an embodiment of the invention, the domain of Cyk-4 that interacts with MKLP1, or the whole Cyk-4 protein, is immobilized on a solid support. The domain
30 of MKLP1 that interacts with CYK-4 or the whole MLKP1 protein that is modified with a suitable label to allow for rapid detection (i.e. radiolabelled, fluorescently

labeled, hapten labelled etc.) is incubated, optionally in the presence of additional factors that may be required for the interaction, and in the presence or absence of the test compounds.

- 5 After an incubation period that allows for interaction of the proteins, the amount of MKLP1 bound to the immobilized CYK-4 is measured by use of the label outlined above or by the use of suitable antibodies in an ELISA type assay. The assay may also be setup in
- 10 the reverse, e.g. with Cyk-4 being labeled or with MKLP1 immobilized, or by performing the binding reaction in solution and then capturing one of the components on a solid support and measuring the amount of the other component that is co-immobilized.
- 15 Due to their ability of inhibiting the function of Cyk-4 to promote GTP hydrolysis by Rho family GTPase or of interfering with the interaction between Cyk-4 and MKLP1, respectively, compounds identified in the above screens have the potential to perturb cytokinesis. In
- 20 tumor cells, this effect may result in a decrease or a stop of tumor growth. In addition, inhibition of cytokinesis may cause the activation of a cell cycle arrest check point that will trigger apoptosis of the tumor cells.
- 25 To further evaluate the potential of the compounds as drugs, the candidate compounds can be assayed for their effect on cytokinesis and other cellular processes in tissue culture of normal or transformed cells. To test the inhibition of tumor cell proliferation, primary
- 30 human tumor cells, are incubated with the compound

identified in the screen and the inhibition of tumor cell proliferation is tested by conventional methods, e.g. bromo-desoxy-uridine or ^3H thymidine incorporation.

Compounds that exhibit an anti-proliferative effect in
5 these assays may be further tested in tumor animal models and used for the therapy of tumors.

Thus, in a further aspect, the invention relates to compounds identified in the above screens for the therapy of tumors and any other situation in
10 which cell overproliferation is observed.

Description of the figures.

Figure 1:

cyk-4(t1689ts) mutant embryos fail to complete
15 cytokinesis. Wildtype embryos (A) and embryos from *cyk-4* mutant hermaphrodites (B) were dissected from young adults, mounted on agarose pads and observed by time-lapse nomarski microscopy. The ingressing cleavage furrow is indicated (arrows). 10 μm scale bars.

20

Figure 2:

cyk-4 mutant embryos produce deeply ingressing cleavage furrows, but do not form a prominent central spindle. Wild type (A, C) and *cyk-4* mutant embryos (B,D) were
25 fixed and stained for actin (green) and DNA (blue)

(A,B); tubulin (green) and DNA (blue) (C,D). 10 μ m scale bars.

Figure 3:

- 5 Positional cloning of the *cyk-4* locus. (A) A schematic of LGIII showing the positions of various loci and the extent of the deficiencies. *cyk-4* is uncovered by tDf10, tDf6, and ctDf2, but not ctDf3. (B) An enlargement of the physical map from the *unc-64* locus until the end of LGIII. The ability of various cosmid pools to rescue *cyk-4* is indicated. (C) A map of the predicted genes on K08E3. All the predicted genes except for K08E3.1 and K08E3.5 were inactivated by RNAi and only RNAi of K08E3.6 produced multinucleate embryos. (D) A schematic representation of the domain structure of CYK-4 and its human ortholog. The position of the point mutation identified in *cyk-4(t1689ts)* is indicated.

20 Figure 4:

- cyk-4(RNAi)* causes disorganization of the proximal gonad and affects formation of the central spindle. Young adults were injected with *cyk-4* dsRNA and the injected animals were analyzed 30 hours after injection (B). The gonad of an uninjected worm is shown for comparison (A). Wild-type embryos (C) and embryos from *cyk-4(RNAi)* injected animals (D) were fixed and stained for tubulin. 10 μ m scale bars.

Figure 5:

CYK-4 enhances GTP hydrolysis by Rho, Rac, and Cdc42. The GTPases were preloaded with ^{32}P - α -GTP and then GST-CYK-4-GAP or GST was added at the indicated concentration. Samples were taken at two minute intervals, the labeled nucleotide was resolved by thin layer chromatography, the fraction of GTP and GDP was quantitated. This graph shows the fraction of GTP hydrolyzed at the 2 minute time point as a function of CYK-4 concentration. These data are representative of at least three independent experiments.

Figure 6:

rho(RNAi) causes cytokinesis defects and *cdc42(RNAi)* causes defects in spindle positioning. Young adults were injected with the indicated dsRNAs (see table 2) and the embryos produced by the injected worms were analyzed by time lapse nomarski microscopy. Images from a wild-type (A), *rho(RNAi)* (B) and a *cdc42(RNAi)* (C) embryo are shown. 10 μm scale bars.

Figure 7:

CYK-4 localizes to the central spindle and division remnants. (A-F) Wild-type embryos were fixed and stained for CYK-4 (green), tubulin (red) and DNA (blue). The localization of CYK-4 to the central spindle (arrow) in a one cell embryo (D) and a two cell embryo (F) is shown. The localization of CYK-4 to the

division remnant from the polar body (A), and between the AB and P1 blastomeres is indicated with arrows. (E). (G) An embryo from a line expressing CYK-4:GFP is stained with anti-GFP antibodies. The same structures are seen as with CYK-4 antibodies (arrow). (H) The intrinsic fluorescence of the gonad of a worm expressing CYK-4:GFP. CYK-4 is seen at the incomplete membranes of the syncytial gonad (arrow) and in oocyte nuclei. 10 μ m scale bars.

10

Figure 8:

Time lapse analysis of CYK-4:GFP. An embryo from a line expressing CYK-4:GFP was imaged using low light level microscopy. The central spindle localization of CYK-4 is observed prior to furrow ingression. 10 μ m scale bars.

15

Figure 9:

CYK-4 and ZEN-4/CeMKLP1 colocalize and are interdependent for their localization. An embryo expressing CYK-4:GFP stained for GFP (A), ZEN-4/CeMKLP1 (B) and the merged image (C). CYK-4 and ZEN-4/CeMKLP1 colocalize at division remnants (arrow) and a central spindle (arrowheads) structures. ZEN-4 localization to the central spindle is CYK-4 dependent (arrow). Wild-type (D) and *cyk-4(t1689ts)* embryos (E) were fixed and stained for ZEN-4/CeMKLP1 (green), tubulin (red) and DNA (blue). AIR-2 localization to the central spindle is CYK-4 independent (arrow). Wild-type (F) and

20

25

cyk-4(t1689ts) embryos (G) were fixed and stained for AIR-2 (green), tubulin (red) and DNA (blue). CYK-4 maintenance to division remnants (arrowheads) is ZEN-4/CeMKLP1 dependent. *zen-4(or153ts)* worms were

5 maintained at 16 C and either fixed immediately (H) or shifted to 25 C for 18 minutes (I). Embryos were fixed and stained for CYK-4 (green), tubulin (red) and DNA (blue). 10 µm scale bars.

10 Figure 10:

Model for the function of CYK-4 in central spindle formation and cytokinesis.

15 In the Examples, if not otherwise stated, the following materials and methods were used:

a) Strains and alleles

The *cyk-4(t1689ts)* allele was identified in a search for maternal effect lethal mutations on chromosome III
20 (see (Gönczy et al., 1999b) for details). The strains DR104, BW1535, BW1369, and RW7000 were obtained from the CGC. The strain EU699 containing the *zen-4(or153ts)* allele will be described in detail elsewhere (Aaron Severson, D.H. and Bruce Bowerman (U.
25 of Oregon)). The end points of the deficiency tDf10 (Heinke Schnabel, unpublished data) are not molecularly defined, but it uncovers *cyk-4*, *lit-1*, and *bli-5* and it does not uncover *unc-64*.

b) Antisera

Cyk-4 specific antisera were produced in rabbits using a His6-Cyk-4 fusion protein as immunogen (containing amino acids 407-613 of cyk-4). A GST-Cyk-4 fusion containing amino acids 407-681 of Cyk-4 was coupled to a Hi-Trap NHS resin (Amersham-Pharmacia) and used to affinity purify anti-Cyk-4 antibodies which were used at a final concentration of 1:300. The antibodies used for the studies are specific for Cyk-4 since the staining can be blocked with antigen, a similar pattern is observed when anti-GFP antibodies are used to detect a Cyk-4:GFP fusion construct, and the staining pattern is disrupted in cyk-4 mutant embryos. The rat monoclonal YOL 1/34 anti-tubulin antibody was used at a dilution of 1:200-500. Anti-GFP antibodies (Roche) were used at a dilution of 1:500. Antisera specific for Zen-4/MKlp1 was generously provided by Bill Saxton and Susan Strome (Univ. of Indiana) and used at a dilution of 1:4000. Antisera specific for Air-2 was generously provided by Andy Golden (NIH) and used at a dilution of 1:1000.

c) Genetic mapping of Cyk-4

The *cyk-4* locus maps under the deficiency *tDf6* which deletes a large fraction of the distal right arm of LGIII. Recombination mapping using *unc-32(e189)* *cyk-4(t1689ts)/dpy-18(e364)* *unc-25(e156)* placed *cyk-4* distal to (or very close to) *unc-25* (23/23 *Dpy* non *Unc*'s carried the *cyk-4* mutation). Recombination between *dpy-18* *cyk-4/RW7000* which carries several *Tc1*

elements including one on the cosmid F14F7 gave rise to 45 Dpy non-Ts animals, 3 of which lacked the TC1 insertion on F14F7, indicating that the *cyk-4* gene is distal to this cosmid. Crosses to strains carrying the deficiencies *ctDf3*, *ctDf2*, *tDf10* revealed that *cyk-4(t1689ts)* is not uncovered by *ctDf3* and is uncovered by both *ctDf2* and *tDf10*. Since *tDf10* does not uncover *unc-64*, *cyk-4(t1689ts)* must be distal to *unc-64*.

10 d) Time Lapse recordings

Time lapse nomarski imaging was performed as described previously (Jantsch-Plunger and Glotzer, 1999). Time lapse imaging of *Cyk-4:GFP* was performed on a Zeiss Axiovert microscope using a 100X/1.3 neofluar objective. The illumination source, an Atto-arc HBO-103, was reduced to 50% intensity. An intensified cooled CCD camera (GenIV pentamax, Princeton Instruments) was used for image acquisition. The camera and other electronics were controlled with MetaMorph software (Universal Imaging). Typical acquisition times were 40-80 msec. Each 10 seconds, 4-5 fluorescent images were acquired at different focal planes and a nomarski image was acquired. The fluorescent images were projected onto a single frame using the maximum intensity from the stack of images. Under these conditions, embryos could be filmed for more than one hour without affecting the cell cycle timing or pattern of cell divisions.

e) Rescue Experiments

To identify the *cyk-4* gene in this region cosmid DNA (from stocks kindly provided by Alan Coulson, Sanger Center) was coinjected with the *rol-6(su1006)* dominant marker (Mello et al., 1991) into the gonad of *unc-32* *cyk-4/qC1* worms. Heterozygous F1 hermaphrodites that carried the *rol-6* dominant marker were cloned to individual plates at 25°C and the presence of Unc progeny, indicating zygotic rescue of the *cyk-4* mutation, was assessed. Individual *unc-32*, *cyk-4* worms carrying the extrachromosomal arrays were cloned to individual plates to assess the extent of germline rescue. The *cyk-4* genomic rescue construct MP17, contains a 4.9 kb genomic *Xba*I fragment excised from K08E3 and inserted into pBS-KS+.

f) RNA interference

Approximately 500 bp of DNA corresponding to predicted coding regions of Rho (Y51H4A.B), Rac-1 (C09G12.8B), Cdc42 (R07G3.1), F22E12.2, Y32F6B.3, K08D3.9, K08E3.2, K08E3.3, K08E3.4, K08E3.6, K08E3.7, K08E3.8 were amplified by PCR and cloned into pGEM-T (Promega). Double stranded RNA was transcribed (Ambion) and annealed, and injected into the gonads of wildtype N2 hermaphrodites as described (Fire et al., 1998).

g) Production of Cyk-4:GFP transgenes

The GFP cassette from vector pPD119.16 (a generous gift from A. Fire) was excised with BspLUIII and inserted into the unique NcoI site of MP17 (see above). This
5 construct was linearized with XbaI, and complex arrays containing linearized genomic DNA and linearized rol-6(sul006) DNA were mixed in a ratio of 1:100:1 and injected into *unc-32(e189) cyk-4(t1689ts)/qC1* hermaphrodites. Rolling F1 heterozygotes were singled
10 out at 25°C and rolling Unc F2 animals were picked. A line MG110, was obtained that gave stable rescue of the *cyk-4(t1689ts)* mutation.

The structure of the *cyk-4* gene was established by analysis of a large number of EST sequences available
15 in the sequence databases at the Sanger Center and the National Institute of Genetics and by sequencing the clones yk63D6 and yk104g12 (kindly provided by Yuji Kohara). The structure of the gene is identical to the structure predicted by the *C. elegans* genome
20 consortium.

h) Immunolocalization

Immunolocalization studies were performed as previously described (Jantsch-Plunger and Glotzer, 1999).
25 Briefly, gravid hermaphrodites were placed on aminopropyl-silane treated slides, a coverslip was added, and sufficient pressure to extrude the embryos was applied. The slide was placed into liquid nitrogen. The coverslip was removed while the sample

was still frozen, the preparation fixed with -20°C methanol and then antibody staining was performed according to standard procedures.

5 i) Biochemical analysis of Cyk-4

The coding regions of Rho, Rac, and Cdc42 were PCR amplified and cloned into pET28b with an C-terminal polyhistidine tag. The GTPases were expressed at 25°C and purified using Ni^{2+} -NTA-agarose (QIAGEN). Proteins
10 were dialyzed into 50 mM Tris pH 7.5, 50 mM NaCl, 5 mM MgCl_2 and quick frozen. The GAP domain of Cyk-4 (amino acids 407-681) was cloned into pGEX4T-1. Proteins were expressed at 25°C and purified using GSH-agarose (Sigma). Proteins were dialyzed into 50 mM Tris pH
15 7.5, 50 mM NaCl, 5 mM MgCl_2 , 1 mM DTT and quick frozen. To assess GAP activity, 15 pmol of the GTPases were loaded with 1 pmol ^{32}P - α -GTP in 20 mM Tris pH 7.6, 4 mM EDTA, 25 mM NaCl, 1 mM DTT, 1 mM ATP, 0.1 mg/ml BSA at room temperature. The sample was place on ice and MgCl_2
20 was added to 17 mM. GST-Cyk-4-GAP was added at the indicated concentrations and, at intervals, samples were taken by dilution into 2% SDS, 20 mM EDTA. Aliquots were spotted onto TLC plates (PEI-cellulose, Machery-Nagel) and developed in 1M LiCl. The plates
25 were dried and exposed using a Storm Phosphoimager (Molecular Dynamics) and the data analysis was performed using the public domain NIH Image program (developed at the U.S. National Institutes of Health; <http://rsb.info.nih.gov/nih-image/>).

Example 1

cyk-4 mutants initiate, but do not complete,
cytokinesis

The *cyk-4(t1689ts)* allele was isolated in a screen for
5 maternal effect embryonic lethal mutations on
chromosome III (Gönczy et al., 1999b). The *cyk-4* locus
is defined by a single, temperature sensitive (*ts*),
allele. The phenotype of embryos derived from
homozygous *cyk-4* hermaphrodites at the restrictive
10 temperature (hereafter referred to as *cyk-4* mutant
embryos) during the first division is shown in figure
1B. *cyk-4* mutant embryos appear normal until
cytokinesis, except that defects in polar body
extrusion are frequently observed (data not shown).
15 The first cleavage furrow forms at the correct time and
place, it ingresses extensively, but, invariably, it
regresses. Quantitation of the extent of furrow
ingression in *cyk-4* mutant embryos reveals that, on
average, furrows ingress to 73+/-13% (n=14) of the egg
20 diameter. A multipolar spindle develops in the second
cell cycle and the process of furrow ingression and
regression occurs again. This pattern is repeated
until the embryos become grossly disorganized.

Although the majority of cell divisions in worm
25 development occur early in embryogenesis, cells of the
germline and many cells in the nervous system are
produced during post embryonic development (Sulston and
Horvitz, 1977). A number of mutations in genes required
for cell division cause worms to become sterile and
30 uncoordinated (O'Connell et al., 1998; Woollard and

Hodgkin, 1999). To determine if *cyk-4* is required post embryonically, temperature shift experiments with worms homozygous for the *cyk-4(t1689ts)* allele were performed (table 1). Homozygous animals grown at 16°C are viable and fertile. Homozygous *cyk-4* animals shifted to 25°C at the L4 stage produce embryos with the cytokinesis defects described above. Homozygous animals shifted to 25°C at earlier stages either fail to hatch or become sterile and uncoordinated, depending on the time of the temperature shift. Thus *cyk-4* is required postembryonically, perhaps due to its role in cell division. Unexpectedly, animals shifted at the L2/L3 stages become highly uncoordinated adults, even though most motor neurons would be expected to have completed all their divisions at the time of the shift. This may suggest that CYK-4 has additional roles besides its role in cell division. However, not out the possibility cannot be ruled out that some of the cells in the ventral nerve cord divide later in *cyk-4* mutants.

To investigate why *cyk-4* mutant embryos fail to complete cytokinesis, actin and tubulin were localized in wild-type and *cyk-4* mutant embryos. Both wild-type and mutant embryos contained deeply ingressing cleavage furrows that stain with an anti-actin antibody (figure 2A,B). The metaphase spindles of *cyk-4* mutant embryos appeared normal (data not shown). However, spindle morphology during early anaphase was significantly different in mutant embryos as compared to wild type. In wild-type embryos (20/20) prominent microtubule bundles form between the separating masses of chromatin, forming the central spindle (figure 2C).

In *cyk-4* mutant embryos (9/10) such bundles were largely reduced and disorganized (figure 2D). It is concluded that CYK-4 is required for the organization of the central spindle during anaphase. Since the central spindle is required for cytokinesis, it is possible that the *cyk-4* mutant embryos fail to complete cytokinesis because they fail to assemble the central spindle.

10 Example 2

Cloning of the *cyk-4* gene

To investigate the molecular basis for the phenotypes described above, it was first sought to map the *cyk-4* locus and clone the affected gene (see methods for details). The *cyk-4* gene maps distal to *unc-64* on the extreme right arm of LG III (figure 3). The *cyk-4* gene was then identified by functional rescue of the zygotic requirement for *cyk-4* using pools of cosmids. A pool of three cosmids (ZK520, W06F12, and K08E3) allowed *cyk-4* homozygotes to hatch and develop to adulthood at 25°C. These cosmids were injected individually and cosmid K08E3 contained rescuing activity. Further subcloning revealed that a 4.9 kb genomic fragment, predicted to contain the complete K08E3.6 gene and no other intact gene, could rescue the *cyk-4* zygotic and germline phenotypes. Finally, the coding region was amplified from DNA derived from *cyk-4(t1689)* homozygotes and sequenced and a single point mutation was identified that differed from the sequence provided by the genome project; this mutation was not observed in another line

derived from the same parental strain. These data show that the defect in *cyk-4(t1689ts)* embryos is due to a point mutation in the K08E3.6 gene.

The predicted protein product of the *cyk-4* gene has a
5 C-terminal domain that contains the consensus motifs of
GTPase activating proteins for Rho family GTPases
(figure 3). Adjacent to the C-terminal GAP domain is a
C1 domain that is predicted to bind to diacylglycerol
or phorbol esters. At the amino terminus of the
10 protein is a 90 amino acid region predicted to form a
coiled-coil domain. The S15L point mutation found in
cyk-4(t1689ts), is located just amino terminal to the
coiled-coil domain. Human and mouse proteins with
structural similarities to *cyk-4* have been described
15 (Toure et al., 1998; Woollorton et al., 1999). These
genes are expressed in a variety of proliferating
tissues. In addition, the *Drosophila* sequence database
contains an entry (ascension no. AC005977 (CLOT 94))
that, together with CYK-4 and the previously mentioned
20 human gene, share a common structure consisting of
approximately 650 amino acids, an NH₂-terminal coiled-
coil domain and a conserved C-terminus containing C1
and GAP domains. The structural conservation of CYK-4
suggests that its function is conserved among
25 metazoans.

In the present invention, the the human and mouse
cDNA's were identified by searching the DNA databases
with the *C.elegans* CYK-4 protein sequence.

Since the *cyk-4(t1689ts)* mutation may contain residual activity RNA-mediated interference (RNAi) was used to deplete embryos of CYK-4 protein. RNAi of the predicted open reading frame K08E3.6 generated

5 multinucleate embryos which exhibited a similar phenotype to that of the *cyk-4* mutant, including loss of the central spindle (figure 4 D) and incomplete cytokinesis (not shown). Interestingly, the gonads of *cyk-4(RNAi)* animals become disorganized 30 hours post-

10 injection (figure 4 B) and irregularly sized embryos are produced, suggesting that CYK-4 acts not only during embryonic and zygotic development, but also in the female germline.

15 Example 3

Biochemical activity of the Cyk-4 GAP domain

The presence of a Rho-family GAP domain suggests that CYK-4 may regulate one or more GTPases of Rho branch of the GTPase superfamily. To determine whether CYK-4 is

20 active as a GAP and whether its GAP activity is restricted to particular members of the Rho subfamily, a recombinant fusion protein containing GST and the CYK-4 GAP domain was prepared and GTP hydrolysis assays were performed with recombinant *C. elegans* Rho, Rac,

25 and Cdc42. The GAP domain of CYK-4 promotes GTP hydrolysis by all three tested GTPases (figure 5). However kinetic differences were observed. At the conditions used in the assays it was found that the CYK-4 GAP domain is more active towards Rac and Cdc42

30 than towards Rho. The human ortholog has a similar

activity profile *in vitro* (Toure et al., 1998). However, since CYK-4 has activity towards all three GTPases, these data are not sufficient to determine the *in vivo* target(s) of the CYK-4 GAP domain.

- 5 Next RNAi was used to determine which, if any, of the Rho family GTPases are required for cytokinesis in the *C. elegans* embryo. RNAi experiments were performed with RhoA, Rac1, Cdc42 and three additional GTPases found in the genome that fall into the Rho subfamily.
- 10 Approximately 90% of *Rho(RNAi)* embryos exhibit cytokinesis defects in the first and/or second cell cycle (table 2 and figure 6). In most embryos, furrow ingression was inhibited. Interestingly, central spindles assemble in *RhoA(RNAi)* embryos (data not
- 15 shown). In contrast, 88% of *Cdc42(RNAi)* embryos complete cytokinesis normally. However, a distinct defect in the early embryo is observed in 54% of *Cdc42(RNAi)* embryos; defects in spindle positioning are observed in P0 and/or P1. A minority (12%) of
- 20 *Cdc42(RNAi)* embryos fail to initiate cytokinesis; in most cases, these embryos appear osmotically swollen even when provided with osmotic support. *Rac(RNAi)* embryos hatch with high efficiency and did not exhibit a detectable phenotype in the early embryo. RNA
- 25 interference experiments with the additional GTPases either alone or in combinations did not reveal any additional defects in the early embryo. Thus RhoA is the only member of the Rho family that is clearly required for cytokinesis and is therefore likely to be
- 30 the critical target for the CYK-4 GAP domain.

Example 4

The subcellular localization of Cyk-4

Next the subcellular localization of CYK-4 protein was determined. CYK-4 localization is cell cycle dependent (figure 7). In interphase cells, CYK-4 is present in the cytoplasm and slightly concentrated in the nucleus. CYK-4 is also highly concentrated in a spot at the anterior of the embryo, DNA labeling reveals that this localization corresponds to the site of polar body extrusion. As embryos enter mitosis, CYK-4 protein concentrates around the mitotic spindle. In early anaphase, CYK-4 concentrates to the central spindle. As the cleavage furrow ingresses, CYK-4 becomes highly concentrated on the central spindle into a structure that often appears ring shaped (not shown). Upon completion of cytokinesis, CYK-4 staining persists at division remnants. CYK-4 organized in ring-like structures averaging 1.2 μ m in diameter are occasionally observed in the cytoplasm (not shown).

To determine if CYK-4 localizes to the central spindle prior to the onset of cleavage furrow ingression, the dynamics of CYK-4 localization in live embryos was investigated. To accomplish this goal a transgenic line expressing a CYK-4:GFP fusion was generated and its localization followed by time lapse microscopy. The CYK-4:GFP fusion is partially functional since *cyk-4 xsEx1[cyk-4:GFP]* animals are viable and fertile at 25°C whereas the parental *cyk-4* strain is inviable at 25°C. However, the fusion construct does not fully

rescue the mutation, since about 40% of embryos produced by this line fail to hatch (table 1).

Low light level fluorescence microscopy was used to visualize CYK-4:GFP in living embryos. Embryos were imaged using a multi-mode imaging system whereby a series of z-sections and a nomarski image were recorded every 10 seconds. The fluorescent images from each time point were projected to form a single image. These recordings reveal that CYK-4 accumulates on the central spindle prior to the initiation of furrowing (figure 8; 3:40). The CYK-4 that localizes to the central spindle becomes compressed into a bright spot which persists at the division remnant. The remnant persists for several cell cycles although instances were observed whereby the remnant (sometimes from the polar body) detaches from the cortex and is observed as a discrete spot in the cytoplasm. This detachment of CYK-4 from division remnants likely accounts for the CYK-4 rings seen in fixed specimens. It is concluded that CYK-4 localization on the central spindle precedes furrow ingression.

Example 5

Cyk-4 and zen-4/CeMklp1 are functionally interdependent

There are remarkable similarities between CYK-4 and the kinesin-like protein ZEN-4/CeMKLP1 (Powers et al., 1998; Raich et al., 1998). zen-4 mutant embryos also initiate, but fail to complete cytokinesis. They also fail to assemble a robust central spindle in early

anaphase. Furthermore, ZEN-4 localizes to the central spindle and persists at division remnants after completion of cytokinesis. To test whether these proteins functionally interact, it was first assessed whether CYK-4 and ZEN-4/CeMKLP1 co-localize. Embryos expressing CYK-4:GFP were fixed and CYK-4 and ZEN-4 were localized simultaneously (using an anti-GFP antibody to detect CYK-4:GFP). The two proteins co-localize both on central spindle structures and on division remnants (Figure 9A-C). It was next investigated if ZEN-4 localization requires functional CYK-4 protein. ZEN-4 staining of *cyk-4* mutant embryos reveals that ZEN-4 localization to the central spindle is absent (figure 9E), although staining of some microtubule bundles in the spindle midzone could be detected using an AIR-2 antibody (figure 9G). Thus, recruitment of ZEN-4 to the central spindle is CYK-4 dependent. Next it was tested whether maintenance of ZEN-4 at division remnants requires functional CYK-4. *cyk-4* mutant embryos grown at 16°C were shifted to 25 °C for 15 minutes prior to fixation and staining with anti- ZEN-4 antibodies. The number of cells and number of division remnants labeled with the anti-ZEN-4 antibody were counted. Embryos maintained at the permissive temperature had a large number of ZEN-4 staining division remnants (table 3) whereas the embryos shifted to the non-permissive temperature lacked defined staining of division remnants. Thus both recruitment of ZEN-4 to the central spindle and its maintenance at division remnants is CYK-4 dependent. The reverse experiment was conducted with a temperature sensitive allele of *zen-4(or153ts)*. In

this case CYK-4 staining at division remnants was observed in *zen-4* mutant embryos at the permissive temperature but this staining disappeared upon a brief shift to the non-permissive temperature (figure 9H,I and table 3). Thus maintenance of CYK-4 at division remnants is ZEN-4 dependent. It is concluded that CYK-4 and ZEN-4/CeMKLP1 colocalize and that the two proteins are interdependent for their localization.

Next, it was determined if embryos carrying mutations in both *cyk-4* and *zen-4* are distinguishable from the single mutants. Two strains were built, one strain was homozygous for *zen-4(or153ts)* and heterozygous for *cyk-4(t1689ts)* and the second strain was homozygous for *cyk-4(t1689ts)* and heterozygous for *zen-4(or153ts)*. Both strains were viable at 16°C, but they failed to produce doubly homozygous larvae. It was found that worms of genotype *unc-32(e189) cyk-4(t1689ts) /qC1 III, zen-4(or153ts)* laid a fraction of embryos that arrested during embryonic development, typically before the comma stage. Thus *cyk-4(t1689ts)* and *zen-4(or153ts)* are synthetically lethal.

Table 1

genotype	stage at time of shift to 25°C	percent viable	phenotype of surviving progeny	N
N2 (wild type)	embryos	98.8%	wild-type	485
<i>cyk-4</i>	(not shifted)	70.2%	fertile	198
<i>cyk-4</i>	embryos	1.5%	sterile, highly Unc	324
<i>cyk-4</i>	L1 larvae	100.0%	sterile, highly Unc	89
<i>cyk-4</i>	L2/L3	100.0%	sterile, highly Unc	55
<i>cyk-4</i>	L4	100.0%	fertile, lay dead embryos	52
<i>cyk-4</i> , <i>xsEx1[cyk- 4:GFP]</i>	embryos	59.4%	fertile	350

- 5 Except for the N2 control, the complete genotype of the strain was *unc-32(e189) cyk-4(t1689ts)*. Gravid hermaphrodites were allowed to lay embryos for 2 hours at the permissive temperature. The adult was then removed and the number of embryos counted. After 24
- 10 hours at the indicated temperature the number of unhatched embryos was then counted.

Table 2

injected locus dsRNA	percent cytokinesis defective (N)	number of time lapse recording s	number cytokinesi s defective	additional phenotypes
RhoA. Y51H4A.B	95% (175)	15	15 (100%)	
Rac-1 C09G12.8 B	Not emb. lethal	5	0	
Cdc42 R07G3.1	12% (74)	22	3 (14%)	symmetric 1st division (5/22); no rotation in P1(12/22); rotation of AB (2/22)
others F22E12.2	Not emb. lethal			
Y32F6B.3	Not emb. lethal			
K03D3.9	Not emb. lethal			

Young adult hermaphrodites were injected with the
 5 indicated dsRNAs and broods of laid embryos were scored
 for embryonic lethality. dsRNAs that induced embryonic
 lethality were further characterized by dissecting
 embryos and scoring for multinucleate embryos and by
 performing time lapse recordings and evaluating
 10 cytokinesis, spindle orientation in the one-cell embryo
 (symmetric or asymmetric first cleavage), and spindle
 positioning in the P1 and AB blastomeres.

Table 3

genotype	temperature	total number of stained remnants	total number of cells	average number of remnants/ cell	number of embryos
N2 (wildtype)	25°C	110	137	0.80	16
<i>zen-4(or198ts)</i>	16°C	61	83	0.73	10
<i>zen-4(or198ts)</i>	25°C (18 min.)	11	147	0.07	24
N2 (wildtype)	25°C	150	205	0.73	22
<i>cyk-4(t1689ts)</i>	16°C	61	98	0.62	10
<i>cyk-4(t1689ts)</i>	25°C (15 min.)	10	176	0.06	19

Wild-type and *zen-4(or153ts)* embryos grown at the indicated temperatures were fixed and stained for Cyk-4. Similarly, Wild-type and *cyk-4(t1689ts)* grown at the indicated temperatures were fixed and stained for Zen-4/CeMK1p1. The number of cells in each embryo and the number of remnants staining with Cyk-4 or Zen-4 antibodies was counted.

References

- Adams, R. R., Tavares, A. A., Salzberg, A., Bellen, H.
5 J., and Glover, D. M. (1998). pavarotti encodes a
kinesin-like protein required to organize the
central spindle and contractile ring for
cytokinesis. Genes Dev 12, 1483-94.
- 10 Aktories, K., and Hall, A. (1989). Botulinum ADP-
ribosyltransferase C3: a new tool to study low
molecular weight GTP-binding proteins. Trends
Pharmacol Sci 10, 415-8.
- 15 Boshier, J.M. and Labouesse, M., (2000), Nat Cell Biol,
Feb; 2(2):E31-6
- Busson, S., Dujardin, D., Moreau, A., Dompierre, J.,
and De Mey, J. R. (1998). Dynein and dynactin are
20 localized to astral microtubules and at cortical
sites in mitotic epithelial cells. Curr Biol 8,
541-4.
- Cao, L. G., and Wang, Y. L. (1996). Signals from the
25 spindle midzone are required for the stimulation

of cytokinesis in cultured epithelial cells. Mol Biol Cell 7, 225-32.

- 5 Carminati, J. L., and Stearns, T. (1997). Microtubules orient the mitotic spindle in yeast through dynein- dependent interactions with the cell cortex. J Cell Biol 138, 629-41.
- 10 Castrillon, D. H., and Wasserman, S. A. (1994). Diaphanous is required for cytokinesis in Drosophila and shares domains of similarity with the products of the limb deformity gene. Development 120, 3367-77.
- 15 Chang, F., Drubin, D., and Nurse, P. (1997). cdc12p, a protein required for cytokinesis in fission yeast, is a component of the cell division ring and interacts with profilin. J Cell Biol 137, 169-82.
- 20 Drechsel, D. N., Hyman, A. A., Hall, A., and Glotzer, M. (1997). A requirement for Rho and Cdc42 during cytokinesis in Xenopus embryos. Curr Biol 7, 12-23.
- 25 Dutartre, H., Davoust, J., Gorvel, J. P., and Chavrier, P. (1996). Cytokinesis arrest and redistribution

of actin-cytoskeleton regulatory components in cells expressing the Rho GTPase CDC42Hs. J Cell Sci 109, 367-77.

- 5 Eckley, D. M., Ainsztein, A. M., Mackay, A. M.,
Goldberg, I. G., and Earnshaw, W. C. (1997).
Chromosomal proteins and cytokinesis: patterns of
cleavage furrow formation and inner centromere
protein positioning in mitotic heterokaryons and
10 mid-anaphase cells. J Cell Biol 136, 1169-83.
- Evangelista, M., Blundell, K., Longtine, M. S., Chow,
C. J., Adames, N., Pringle, J. R., Peter, M., and
Boone, C. (1997). Bni1p, a yeast formin linking
15 cdc42p and the actin cytoskeleton during polarized
morphogenesis. Science 276, 118-22.
- Field, C., Li, R., and Oegema, K. (1999). Cytokinesis
in eukaryotes: a mechanistic comparison. Curr Opin
20 Cell Biol 11, 68-80.
- Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A.,
Driver, S. E., and Mello, C. C. (1998). Potent and
specific genetic interference by double-stranded
25 RNA in *Caenorhabditis elegans*. Nature 391, 806-11.

Fire, A., (1999), Trends Genet, Sep; 15(9):358-63

Fujiwara, T., Tanaka, K., Inoue, E., Kikyo, M., and
Takai, Y. (1999). Bnlp Regulates Microtubule-
Dependent Nuclear Migration through the Actin
Cytoskeleton in *Saccharomyces cerevisiae*. Mol Cell
Biol 19, 8016-8027.

Giansanti, M. G., Bonaccorsi, S., Williams, B.,
Williams, E. V., Santolamazza, C., Goldberg, M.
L., and Gatti, M. (1998). Cooperative interactions
between the central spindle and the contractile
ring during *Drosophila* cytokinesis. Genes Dev 12,
396-410.

Glotzer, M. (1997). The mechanism and control of
cytokinesis. Curr Opin Cell Biol 9, 815-23.

Gönczy, P., Pichler, S., Kirkham, M., and Hyman, A. A.
(1999). Cytoplasmic dynein is required for
distinct aspects of MTOC positioning, including
centrosome separation, in the one cell stage
Caenorhabditis elegans embryo. J Cell Biol 147,
135-50.

- Gönczy, P., Schnabel, H., Kaletta, T., Amores, A. D.,
Hyman, T., and Schnabel, R. (1999). Dissection of
cell division processes in the one cell stage
Caenorhabditis elegans embryo by mutational
5 analysis. J Cell Biol 144, 927-46.
- Hyman, A. A. (1989). Centrosome movement in the early
divisions of Caenorhabditis elegans: a cortical
site determining centrosome position. J Cell Biol
10 109, 1185-93.
- Hyman, A. A., and White, J. G. (1987). Determination of
cell division axes in the early embryogenesis of
Caenorhabditis elegans. J Cell Biol 105, 2123-35.
- 15
- Imamura, H., Tanaka, K., Hihara, T., Umikawa, M.,
Kamei, T., Takahashi, K., Sasaki, T., and Takai,
Y. (1997). Bnlp and Bnrlp: downstream targets of
the Rho family small G-proteins which interact
20 with profilin and regulate actin cytoskeleton in
Saccharomyces cerevisiae. Embo J 16, 2745-55.
- Jantsch-Plunger, V., and Glotzer, M. (1999). Depletion
of syntaxins in the early Caenorhabditis elegans
embryo reveals a role for membrane fusion events
25 in cytokinesis. Curr Biol 9, 738-45.

- Kishi, K., Sasaki, T., Kuroda, S., Itoh, T., and Takai, Y. (1993). Regulation of cytoplasmic division of *Xenopus* embryo by rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI). *J Cell Biol* 120, 1187-95.
- Kosako, H., Goto, H., Yanagida, M., Matsuzawa, K., Fujita, M., Tomono, Y., Okigaki, T., Odai, H., Kaibuchi, K., and Inagaki, M. (1999). Specific accumulation of Rho-associated kinase at the cleavage furrow during cytokinesis: cleavage furrow-specific phosphorylation of intermediate filaments. *Oncogene* 18, 2783-8.
- Kuriyama, R., Dragas-Granoic, S., Maekawa, T., Vassilev, A., Khodjakov, A., and Kobayashi, H. (1994). Heterogeneity and microtubule interaction of the CHO1 antigen, a mitosis-specific kinesin-like protein. Analysis of subdomains expressed in insect sf9 cells. *J Cell Sci* 107, 3485-99.
- Lamarche, N., and Hall, A. (1994). GAPs for rho-related GTPases. *Trends Genet* 10, 436-40.
- Larkin, K., and Danilchik, M.V. (1999), *Dev Biol.* 214:215-226

- Lee, K. S., Yuan, Y. L., Kuriyama, R., and Erikson, R. L. (1995). Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. *Mol Cell Biol* 15, 7143-51.
- 5
- Mabuchi, I., Hamaguchi, Y., Fujimoto, H., Morii, N., Mishima, M., and Narumiya, S. (1993). A rho-like protein is involved in the organisation of the contractile ring in dividing sand dollar eggs. *Zygote* 1, 325-31.
- 10
- Mackay, A. M., Ainsztein, A. M., Eckley, D. M., and Earnshaw, W. C. (1998). A dominant mutant of inner centromere protein (INCENP), a chromosomal protein, disrupts prometaphase congression and cytokinesis. *J Cell Biol* 140, 991-1002.
- 15
- Martineau-Thuillier, S., Andreassen, P. R., and Margolis, R. L. (1998). Colocalization of TD-60 and INCENP throughout G2 and mitosis: evidence for their possible interaction in signalling cytokinesis. *Chromosoma* 107, 461-70.
- 20
- Mello, C. C., Kramer, J. M., Stinchcomb, D., and Ambros, V. (1991). Efficient gene transfer in *C.elegans*: extrachromosomal maintenance and integration of transforming sequences. *Embo J* 10, 3959-70.
- 25

Miller, R. K., Matheos, D., and Rose, M. D. (1999). The
cortical localization of the microtubule
orientation protein, Kar9p, is dependent upon
5 actin and proteins required for polarization. J
Cell Biol 144, 963-75.

Moorman, J. P., Bobak, D. A., and Hahn, C. S. (1996).
Inactivation of the small GTP binding protein Rho
10 induces multinucleate cell formation and apoptosis
in murine T lymphoma EL4. J Immunol 156, 4146-53.

Nislow, C., Lombillo, V. A., Kuriyama, R., and
McIntosh, J. R. (1992). A plus-end-directed motor
15 enzyme that moves antiparallel microtubules in
vitro localizes to the interzone of mitotic
spindles. Nature 359, 543-7.

O'Connell, C. B., Wheatley, S. P., Ahmed, S., and Wang,
20 Y. L. (1999). The small GTP-binding protein rho
regulates cortical activities in cultured cells
during division. J Cell Biol 144, 305-13.

O'Connell, K. F., Leys, C. M., and White, J. G. (1998).
25 A genetic screen for temperature-sensitive cell-
division mutants of *Caenorhabditis elegans*.
Genetics 149, 1303-21.

Powers, J., Bossinger, O., Rose, D., Strome, S., and Saxton, W. (1998). A nematode kinesin required for cleavage furrow advancement. *Curr Biol* 8, 1133-6.

- 5 Prokopenko, S. N., Brumby, A., O'Keefe, L., Prior, L., He, Y., Saint, R., and Bellen, H. J. (1999). A putative exchange factor for Rho1 GTPase is required for initiation of cytokinesis in *Drosophila*. *Genes Dev* 13, 2301-14.

10

Raich, W. B., Moran, A. N., Rothman, J. H., and Hardin, J. (1998). Cytokinesis and midzone microtubule organization in *Caenorhabditis elegans* require the kinesin-like protein ZEN-4. *Mol Biol Cell* 9, 2037-49.

15

Rappaport, R. (1985). Repeated furrow formation from a single mitotic apparatus in cylindrical sand dollar eggs. *J Exp Zool* 234, 167-71.

20

Reddien, P., and Horvitz, H. (2000). CED-2/CrkII and CED-10/Rac control phagocytosis and cell migration in *Caenorhabditis elegans*. *Nature Cell Biology* 2, 131-136.

25

Rieder, C. L., Khodjakov, A., Paliulis, L. V., Fortier, T. M., Cole, R. W., and Sluder, G. (1997). Mitosis in vertebrate somatic cells with two spindles: implications for the metaphase/anaphase transition checkpoint and cleavage. Proc Natl Acad Sci U S A 94, 5107-12.

Savoian, M. S., Earnshaw, W. C., Khodjakov, A., and Rieder, C. L. (1999). Cleavage furrows formed between centrosomes lacking an intervening spindle and chromosomes contain microtubule bundles, INCENP, and CHO1 but not CENP-E. Mol Biol Cell 10, 297-311.

Schumacher, J. M., Golden, A., and Donovan, P. J. (1998). AIR-2: An Aurora/Ipl1-related protein kinase associated with chromosomes and midbody microtubules is required for polar body extrusion and cytokinesis in *Caenorhabditis elegans* embryos. J Cell Biol 143, 1635-46.

Sharp, P.A., (1999), Genes Dev, Jan 15; 13(2):139-41

Settleman, J., and Foster, R., (1995), Methods Enzymol; 256:105-13

Skop, A. R., and White, J. G. (1998). The dynactin complex is required for cleavage plane specification in early *Caenorhabditis elegans* embryos. *Curr Biol* 8, 1110-6.

5

Sugihara, K., Nakatsuji, N., Nakamura, K., Nakao, K., Hashimoto, R., Otani, H., Sakagami, H., Kondo, H., Nozawa, S., Aiba, A., and Katsuki, M. (1998). Rac1 is required for the formation of three germ layers during gastrulation. *Oncogene* 17, 3427-33.

10

Sulston, J.E., and Horvitz, H.R., (1977), *Dev Biol.* 56:110-156

15 Swan, K. A., Severson, A. F., Carter, J. C., Martin, P. R., Schnabel, H., Schnabel, R., and Bowerman, B. (1998). *cyk-1*: a *C. elegans* FH gene required for a late step in embryonic cytokinesis. *J Cell Sci* 111, 2017-27.

20

Tatsumoto, T., Xie, X., Blumenthal, R., Okamoto, I., and Miki, T. (1999). Human ECT2 is an exchange factor for rho GTPases, phosphorylated in G2/M phases, and involved in cytokinesis [In Process Citation]. *J Cell Biol* 147, 921-8.

25

Tourel, A., Dorseuil, O., Morin, L., Timmons, P., Jegou, B., Reibel, L., and Gacon, G. (1998). MgcRacGAP, a new human GTPase-activating protein for Rac and Cdc42 similar to Drosophila rotundRacGAP gene product, is expressed in male germ cells. J Biol Chem 273, 6019-23.

Van Aelst, L., and D'Souza-Schorey, C. (1997). Rho GTPases and signaling networks. Genes Dev 11, 2295-322.

Waddle, J. A., Cooper, J. A., and Waterston, R. H. (1994). Transient localized accumulation of actin in Caenorhabditis elegans blastomeres with oriented asymmetric divisions. Development 120, 2317-28.

Watanabe, N., Madaule, P., Reid, T., Ishizaki, T., Watanabe, G., Kakizuka, A., Saito, Y., Nakao, K., Jockusch, B. M., and Narumiya, S. (1997). p140mDia, a mammalian homolog of Drosophila diaphanous, is a target protein for Rho small GTPase and is a ligand for profilin. Embo J 16, 3044-56.

25

Wheatley, S. P., and Wang, Y. L. (1996). Midzone microtubules are continuously required for

cytokinesis in cultured epithelial cells. J. Cell Biol. 135, 981-989.

5 Woollard, A., and Hodgkin, J. (1999). Stu-7/air-2 is a
C. elegans aurora homologue essential for
chromosome segregation during embryonic and post-
embryonic development. Mech Dev 82, 95-108.

10 Woollerton, E.J., Haliotis, T., and Mueller, C.R.,
(1999), DNA Cell Biol. 18:265-273

1

EPO - Munich
31

19. Juni 2000

SEQUENCE LISTING

<110> Boehringer Ingelheim International GmbH

<120> Cyk-4 polypeptides, DNA molecules encoding them and their use in screening methods

<130> Case 14/057

<140>

<141>

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 3050

<212> DNA

<213> Homo sapiens

<220>

<221> 5'UTR

<222> (1)..(70)

<220>

<221> CDS

<222> (71)..(1969)

<220>

<221> 3'UTR

<222> (1970)..(3050)

<400> 1

taaagggggg tgccagacca ggtgcgtctg ccgctggatt gtgataggaa gcagagtgtt 60

cgtgtgaaag atg gat act atg atg ctg aat gtg cgg aat ctg ttt gag 109

Met Asp Thr Met Met Leu Asn Val Arg Asn Leu Phe Glu

1

5

10

cag ctt gtg cgc cgg gtg gag att ctc agt gaa gga aat gaa gtc caa 157

Gln Leu Val Arg Arg Val Glu Ile Leu Ser Glu Gly Asn Glu Val Gln

15

20

25

ttt atc cag ttg gcg aag gac ttt gag gat ttc cgt aaa aag tgg cag 205

Phe Ile Gln Leu Ala Lys Asp Phe Glu Asp Phe Arg Lys Lys Trp Gln

30

35

40

45

agg act gac cat gag ctg ggg aaa tac aag gat ctt ttg atg aaa gca 253

Arg Thr Asp His Glu Leu Gly Lys Tyr Lys Asp Leu Leu Met Lys Ala

50

55

60

gag act gag cga agt gct ctg gat gtt aag ctg aag cat gca cgt aat	301
Glu Thr Glu Arg Ser Ala Leu Asp Val Lys Leu Lys His Ala Arg Asn	
65 70 75	
cag gtg gat gta gag atc aaa cgg aga cag aga gct gag gct gac tgc	349
Gln Val Asp Val Glu Ile Lys Arg Arg Gln Arg Ala Glu Ala Asp Cys	
80 85 90	
gaa aag ctg gaa cga cag att cag ctg att cga gag atg ctc atg tgt	397
Glu Lys Leu Glu Arg Gln Ile Gln Leu Ile Arg Glu Met Leu Met Cys	
95 100 105	
gac aca tct ggc agc att caa cta agc gag gag caa aaa tca gct ctg	445
Asp Thr Ser Gly Ser Ile Gln Leu Ser Glu Glu Gln Lys Ser Ala Leu	
110 115 120 125	
gct ttt ctc aac aga ggc caa cca tcc agc agc aat gct ggg aac aaa	493
Ala Phe Leu Asn Arg Gly Gln Pro Ser Ser Ser Asn Ala Gly Asn Lys	
130 135 140	
aga cta tca acc att gat gaa tct ggt tcc att tta tca gat atc agc	541
Arg Leu Ser Thr Ile Asp Glu Ser Gly Ser Ile Leu Ser Asp Ile Ser	
145 150 155	
ttt gac aag act gat gaa tca ctg gat tgg gac tct tct ttg gtg aag	589
Phe Asp Lys Thr Asp Glu Ser Leu Asp Trp Asp Ser Ser Leu Val Lys	
160 165 170	
act ttc aaa ctg aag aag aga gaa aag agg cgc tct act agc cga cag	637
Thr Phe Lys Leu Lys Lys Arg Glu Lys Arg Arg Ser Thr Ser Arg Gln	
175 180 185	
ttt gtt gat ggt ccc cct gga cct gta aag aaa act cgt tcc att ggc	685
Phe Val Asp Gly Pro Pro Gly Pro Val Lys Lys Thr Arg Ser Ile Gly	
190 195 200 205	
tct gca gta gac cag ggg aat gaa tcc ata gtt gca aaa act aca gtg	733
Ser Ala Val Asp Gln Gly Asn Glu Ser Ile Val Ala Lys Thr Thr Val	
210 215 220	
act gtt ccc aat gat ggc ggg ccc atc gaa gct gtg tcc act att gag	781
Thr Val Pro Asn Asp Gly Gly Pro Ile Glu Ala Val Ser Thr Ile Glu	
225 230 235	
act gtg cca tat tgg acc agg agc cga agg aaa aca ggt act tta caa	829
Thr Val Pro Tyr Trp Thr Arg Ser Arg Arg Lys Thr Gly Thr Leu Gln	
240 245 250	
cct tgg aac agt gac tcc acc ctg aac agc agg cag ctg gag cca aga	877
Pro Trp Asn Ser Asp Ser Thr Leu Asn Ser Arg Gln Leu Glu Pro Arg	
255 260 265	
act gag aca gac agt gtg ggc acg cca cag agt aat gga ggg atg cgc	925
Thr Glu Thr Asp Ser Val Gly Thr Pro Gln Ser Asn Gly Gly Met Arg	
270 275 280 285	

ctg cat gac ttt gtt tct aag acg gtt att aaa cct gaa tcc tgt gtt	973
Leu His Asp Phe Val Ser Lys Thr Val Ile Lys Pro Glu Ser Cys Val	
290 295 300	
cca tgt gga aag cgg ata aaa ttt ggc aaa tta tct ctg aag tgt cga	1021
Pro Cys Gly Lys Arg Ile Lys Phe Gly Lys Leu Ser Leu Lys Cys Arg	
305 310 315	
gac tgt cgt gtg gtc tct cat cca gaa tgt cgg gac cgc tgt ccc ctt	1069
Asp Cys Arg Val Val Ser His Pro Glu Cys Arg Asp Arg Cys Pro Leu	
320 325 330	
ccc tgc att cct acc ctg ata gga aca cct gtc aag att gga gag gga	1117
Pro Cys Ile Pro Thr Leu Ile Gly Thr Pro Val Lys Ile Gly Glu Gly	
335 340 345	
atg ctg gca gac ttt gtg tcc cag act tct cca atg atc ccc tcc att	1165
Met Leu Ala Asp Phe Val Ser Gln Thr Ser Pro Met Ile Pro Ser Ile	
350 355 360 365	
gtt gtg cat tgt gta aat gag att gag caa aga ggt ctg act gag aca	1213
Val Val His Cys Val Asn Glu Ile Glu Gln Arg Gly Leu Thr Glu Thr	
370 375 380	
ggc ctg tat agg atc tct ggc tgt gac cgc aca gta aaa gag ctg aaa	1261
Gly Leu Tyr Arg Ile Ser Gly Cys Asp Arg Thr Val Lys Glu Leu Lys	
385 390 395	
gag aaa ttc ctc aga gtg aaa act gta ccc ctc ctc agc aaa gtg gat	1309
Glu Lys Phe Leu Arg Val Lys Thr Val Pro Leu Leu Ser Lys Val Asp	
400 405 410	
gat atc cat gct atc tgt agc ctt cta aaa gac ttt ctt cga aac ctc	1357
Asp Ile His Ala Ile Cys Ser Leu Leu Lys Asp Phe Leu Arg Asn Leu	
415 420 425	
aaa gaa cct ctt ctg acc ttt cgc ctt aac aga gcc ttt atg gaa gca	1405
Lys Glu Pro Leu Leu Thr Phe Arg Leu Asn Arg Ala Phe Met Glu Ala	
430 435 440 445	
gca gaa atc aca gat gaa gac aac agc ata gct gcc atg tac caa gct	1453
Ala Glu Ile Thr Asp Glu Asp Asn Ser Ile Ala Ala Met Tyr Gln Ala	
450 455 460	
gtt ggt gaa ctg ccc cag gcc aac agg gac aca tta gct ttc ctc atg	1501
Val Gly Glu Leu Pro Gln Ala Asn Arg Asp Thr Leu Ala Phe Leu Met	
465 470 475	
att cac ttg cag aga gtg gct cag agt cca cat act aaa atg gat gtt	1549
Ile His Leu Gln Arg Val Ala Gln Ser Pro His Thr Lys Met Asp Val	
480 485 490	
gcc aat ctg gct aaa gtc ttt ggc cct aca ata gtg gcc cat gct gtg	1597
Ala Asn Leu Ala Lys Val Phe Gly Pro Thr Ile Val Ala His Ala Val	
495 500 505	

```

ccc aat cca gac cca gtg aca atg tca cag gac atc aag cgt caa ccc 1645
Pro Asn Pro Asp Pro Val Thr Met Ser Gln Asp Ile Lys Arg Gln Pro
510                    515                    520                    525

aag gtg gtt gag cgc ctg ctt tcc ttg cct ctg gag tat tgg agt cag 1693
Lys Val Val Glu Arg Leu Leu Ser Leu Pro Leu Glu Tyr Trp Ser Gln
                    530                    535                    540

ttc atg atg gtg gag caa gag aac att gac ccc cta cat gtc att gaa 1741
Phe Met Met Val Glu Gln Glu Asn Ile Asp Pro Leu His Val Ile Glu
                    545                    550                    555

aac tca aat gcc ttt tca aca cca cag aca cca gat att aaa gtg agt 1789
Asn Ser Asn Ala Phe Ser Thr Pro Gln Thr Pro Asp Ile Lys Val Ser
                    560                    565                    570

tta ctg gga cct gtg acc act cct gaa cat cag ctt ctc aag act cct 1837
Leu Leu Gly Pro Val Thr Thr Pro Glu His Gln Leu Leu Lys Thr Pro
575                    580                    585

tca tct agt tcc ctg tca cag aga gtc cgt tcc acc ctc acc aag aac 1885
Ser Ser Ser Ser Leu Ser Gln Arg Val Arg Ser Thr Leu Thr Lys Asn
590                    595                    600                    605

act cct aga ttt ggg agc aaa agc aag tct gcc act aac cta gga cga 1933
Thr Pro Arg Phe Gly Ser Lys Ser Lys Ser Ala Thr Asn Leu Gly Arg
610                    615                    620

caa ggc aac ttt ttt gct tct cca atg ctc aag tga agtcacatct 1979
Gln Gly Asn Phe Phe Ala Ser Pro Met Leu Lys
625                    630

gcctgttact tcccagcatt gactgactat aagaaaggac acatctgtac tctgctctgc 2039
agcctcctgt actcattact acttttagca ttctccaggc ttttactcaa gtttaattgt 2099
gcatgaggggt tttattaaaa ctatatatat ctccccttcc ttctcctcaa gtcacataat 2159
atcagcactt tgtgctggtc attgttgga gcttttagat gagacatctt tccaggggta 2219
gaagggttag tatggaattg gttgtgattc tttttgggga aggggggttat tgttcctttg 2279
gcttaaagcc aaatgctgct catagaatga tcttttctta gtttcattta gaactgattt 2339
ccgtgagaca atgacagaaa ccctacctat ctgataagat tagcttgtct cagggtggga 2399
agtgggaggg cagggcaaag aaaggattag accagaggat ttaggatgcc tccttctaag 2459
aaccagaagt tctcattccc cattatgaac tgagctataa tatggagctt tcataaaaaat 2519
gggatgcatt gaggacagaa ctagtgatgg gagtatgctg agctttgatt tggatgatta 2579
ggtctttaat agtgttgagt ggcacaacct tgtaaatgtg aaagtacaac tcgtatttat 2639
ctctgatgtg ccgctggctg aactttgggt tcatttgggg tcaaagccag tttttctttt 2699
aaaattgaat tcattctgat gcttggcccc cataccccca accttgtcca gtggagccca 2759

```

acttctaaag gtcaatatat catccttttg catcccaact accaataaag agtaggctat 2819
 aagggaagat tgtcaatatt ttgtggtaag aaaagctaca gtcatttttt ctttgcactt 2879
 tggatgctga aatttttccc atggaacata gccacatcta gatagatgtg agctttttct 2939
 tctgttaaaa ttattcttaa tgtctgtaaa aacgattttc ttctgtagaa tgtttgactt 2999
 cgtattgacc cttatctgta aaacacctat ttgggataat atttggcttt a 3050

<210> 2
 <211> 632
 <212> PRT
 <213> Homo sapiens

<400> 2

Met	Asp	Thr	Met	Met	Leu	Asn	Val	Arg	Asn	Leu	Phe	Glu	Gln	Leu	Val	1	5	10	15
Arg	Arg	Val	Glu	Ile	Leu	Ser	Glu	Gly	Asn	Glu	Val	Gln	Phe	Ile	Gln	20	25	30	
Leu	Ala	Lys	Asp	Phe	Glu	Asp	Phe	Arg	Lys	Lys	Trp	Gln	Arg	Thr	Asp	35	40	45	
His	Glu	Leu	Gly	Lys	Tyr	Lys	Asp	Leu	Leu	Met	Lys	Ala	Glu	Thr	Glu	50	55	60	
Arg	Ser	Ala	Leu	Asp	Val	Lys	Leu	Lys	His	Ala	Arg	Asn	Gln	Val	Asp	65	70	75	80
Val	Glu	Ile	Lys	Arg	Arg	Gln	Arg	Ala	Glu	Ala	Asp	Cys	Glu	Lys	Leu	85	90	95	
Glu	Arg	Gln	Ile	Gln	Leu	Ile	Arg	Glu	Met	Leu	Met	Cys	Asp	Thr	Ser	100	105	110	
Gly	Ser	Ile	Gln	Leu	Ser	Glu	Glu	Gln	Lys	Ser	Ala	Leu	Ala	Phe	Leu	115	120	125	
Asn	Arg	Gly	Gln	Pro	Ser	Ser	Ser	Asn	Ala	Gly	Asn	Lys	Arg	Leu	Ser	130	135	140	
Thr	Ile	Asp	Glu	Ser	Gly	Ser	Ile	Leu	Ser	Asp	Ile	Ser	Phe	Asp	Lys	145	150	155	160
Thr	Asp	Glu	Ser	Leu	Asp	Trp	Asp	Ser	Ser	Leu	Val	Lys	Thr	Phe	Lys	165	170	175	
Leu	Lys	Lys	Arg	Glu	Lys	Arg	Arg	Ser	Thr	Ser	Arg	Gln	Phe	Val	Asp	180	185	190	
Gly	Pro	Pro	Gly	Pro	Val	Lys	Lys	Thr	Arg	Ser	Ile	Gly	Ser	Ala	Val	195	200	205	

Asp Gln Gly Asn Glu Ser Ile Val Ala Lys Thr Thr Val Thr Val Pro
 210 215 220
 Asn Asp Gly Gly Pro Ile Glu Ala Val Ser Thr Ile Glu Thr Val Pro
 225 230 235 240
 Tyr Trp Thr Arg Ser Arg Arg Lys Thr Gly Thr Leu Gln Pro Trp Asn
 245 250 255
 Ser Asp Ser Thr Leu Asn Ser Arg Gln Leu Glu Pro Arg Thr Glu Thr
 260 265 270
 Asp Ser Val Gly Thr Pro Gln Ser Asn Gly Gly Met Arg Leu His Asp
 275 280 285
 Phe Val Ser Lys Thr Val Ile Lys Pro Glu Ser Cys Val Pro Cys Gly
 290 295 300
 Lys Arg Ile Lys Phe Gly Lys Leu Ser Leu Lys Cys Arg Asp Cys Arg
 305 310 315 320
 Val Val Ser His Pro Glu Cys Arg Asp Arg Cys Pro Leu Pro Cys Ile
 325 330 335
 Pro Thr Leu Ile Gly Thr Pro Val Lys Ile Gly Glu Gly Met Leu Ala
 340 345 350
 Asp Phe Val Ser Gln Thr Ser Pro Met Ile Pro Ser Ile Val Val His
 355 360 365
 Cys Val Asn Glu Ile Glu Gln Arg Gly Leu Thr Glu Thr Gly Leu Tyr
 370 375 380
 Arg Ile Ser Gly Cys Asp Arg Thr Val Lys Glu Leu Lys Glu Lys Phe
 385 390 395 400
 Leu Arg Val Lys Thr Val Pro Leu Leu Ser Lys Val Asp Asp Ile His
 405 410 415
 Ala Ile Cys Ser Leu Leu Lys Asp Phe Leu Arg Asn Leu Lys Glu Pro
 420 425 430
 Leu Leu Thr Phe Arg Leu Asn Arg Ala Phe Met Glu Ala Ala Glu Ile
 435 440 445
 Thr Asp Glu Asp Asn Ser Ile Ala Ala Met Tyr Gln Ala Val Gly Glu
 450 455 460
 Leu Pro Gln Ala Asn Arg Asp Thr Leu Ala Phe Leu Met Ile His Leu
 465 470 475 480
 Gln Arg Val Ala Gln Ser Pro His Thr Lys Met Asp Val Ala Asn Leu
 485 490 495
 Ala Lys Val Phe Gly Pro Thr Ile Val Ala His Ala Val Pro Asn Pro
 500 505 510

7

```

Asp Pro Val Thr Met Ser Gln Asp Ile Lys Arg Gln Pro Lys Val Val
    515                                520                                525

Glu Arg Leu Leu Ser Leu Pro Leu Glu Tyr Trp Ser Gln Phe Met Met
    530                                535                                540

Val Glu Gln Glu Asn Ile Asp Pro Leu His Val Ile Glu Asn Ser Asn
    545                                550                                555                                560

Ala Phe Ser Thr Pro Gln Thr Pro Asp Ile Lys Val Ser Leu Leu Gly
    565                                570                                575

Pro Val Thr Thr Pro Glu His Gln Leu Leu Lys Thr Pro Ser Ser Ser
    580                                585                                590

Ser Leu Ser Gln Arg Val Arg Ser Thr Leu Thr Lys Asn Thr Pro Arg
    595                                600                                605

Phe Gly Ser Lys Ser Lys Ser Ala Thr Asn Leu Gly Arg Gln Gly Asn
    610                                615                                620

Phe Phe Ala Ser Pro Met Leu Lys
    625                                630

```

```

<210> 3
<211> 2919
<212> DNA
<213> Mus musculus

```

```

<220>
<221> 5'UTR
<222> (1)..(134)

```

```

<220>
<221> CDS
<222> (135)..(2021)

```

```

<220>
<221> 3'UTR
<222> (2022)..(2919)

```

```

<400> 3

```

```

ggaaagcggg ttacactgc cgtagtgag gcgcgtcgct ggtagacagc agccctcctg 60
gggcgcggcg gccggagagt gagcgccgcg ggccggacgg ggttgctgtg gcgcggggcc 120
gggagcctcg aaag atg gat act aca atg gtg aat ttg tgg act ctg ttt 170
          Met Asp Thr Thr Met Val Asn Leu Trp Thr Leu Phe
          1                                5                                10

gag cag ctt gtg cgc cgg atg gag att atc aat gaa gga aat gaa agc 218
Glu Gln Leu Val Arg Arg Met Glu Ile Ile Asn Glu Gly Asn Glu Ser
    15                                20                                25

```

att gaa ttc atc cag gtt gtg aag gac ttc gag gac ttc cga aag aag	266
Ile Glu Phe Ile Gln Val Val Lys Asp Phe Glu Asp Phe Arg Lys Lys	
30 35 40	
tat caa aga acc aac cag gag ctg gag aaa ttc aaa gac cta ttg ttg	314
Tyr Gln Arg Thr Asn Gln Glu Leu Glu Lys Phe Lys Asp Leu Leu Leu	
45 50 55 60	
aaa gca gag act ggg cgg agc gcc ctg gac gtg aag ctg aag cat gcc	362
Lys Ala Glu Thr Gly Arg Ser Ala Leu Asp Val Lys Leu Lys His Ala	
65 70 75	
cgt aat caa gtg gac gtg gag atc aag cgg agg cag cgc gct gag gca	410
Arg Asn Gln Val Asp Val Glu Ile Lys Arg Arg Gln Arg Ala Glu Ala	
80 85 90	
gag tgt gca aag ctg gaa caa cag att cag ctg att cga gac ata ctc	458
Glu Cys Ala Lys Leu Glu Gln Gln Ile Gln Leu Ile Arg Asp Ile Leu	
95 100 105	
atg tgt gac aca tct ggc agt att cag ctg agt gag gaa caa aaa tca	506
Met Cys Asp Thr Ser Gly Ser Ile Gln Leu Ser Glu Glu Gln Lys Ser	
110 115 120	
gct ctc gct ttc ctc aac cga ggc caa gca tcc agt ggc cac gcc ggc	554
Ala Leu Ala Phe Leu Asn Arg Gly Gln Ala Ser Ser Gly His Ala Gly	
125 130 135 140	
aac aat aga ctg tca acg att gat gaa tct ggt tcc att tta tca gat	602
Asn Asn Arg Leu Ser Thr Ile Asp Glu Ser Gly Ser Ile Leu Ser Asp	
145 150 155	
atc agc ttt gac aag act gat gaa tca ctg gac tgg gat tct tct ttg	650
Ile Ser Phe Asp Lys Thr Asp Glu Ser Leu Asp Trp Asp Ser Ser Leu	
160 165 170	
gtg aag aat ttc aaa atg aag aaa cga gag aag agg cgc tcc aac agt	698
Val Lys Asn Phe Lys Met Lys Lys Arg Glu Lys Arg Arg Ser Asn Ser	
175 180 185	
aga cag ttc atc gac ggc cct cct ggg cct gtg aag aaa act tgt tcc	746
Arg Gln Phe Ile Asp Gly Pro Pro Gly Pro Val Lys Lys Thr Cys Ser	
190 195 200	
att ggc tct aca gta gac cag gca aat gaa tca ata gtt gca aaa act	794
Ile Gly Ser Thr Val Asp Gln Ala Asn Glu Ser Ile Val Ala Lys Thr	
205 210 215 220	
aca gtg act gtt ccc agt gat ggg gga ccc att gaa gct gtg tct act	842
Thr Val Thr Val Pro Ser Asp Gly Gly Pro Ile Glu Ala Val Ser Thr	
225 230 235	
att gag aca ttg ccg tcc tgg acc agg agt cgc ggg aag tca gga cct	890
Ile Glu Thr Leu Pro Ser Trp Thr Arg Ser Arg Gly Lys Ser Gly Pro	
240 245 250	

tta	caa	cct	gtg	aac	agt	gac	tcc	gct	ctg	aac	agc	agg	cca	ctg	gag	938
Leu	Gln	Pro	Val	Asn	Ser	Asp	Ser	Ala	Leu	Asn	Ser	Arg	Pro	Leu	Glu	
		255					260					265				
cca	aga	act	gac	aca	gac	aat	ttg	ggc	aca	cct	cag	aat	act	gga	ggc	986
Pro	Arg	Thr	Asp	Thr	Asp	Asn	Leu	Gly	Thr	Pro	Gln	Asn	Thr	Gly	Gly	
		270				275					280					
atg	cgc	ttg	cac	gac	ttc	gtc	tca	aag	acg	gtt	att	aag	cct	gaa	tct	1034
Met	Arg	Leu	His	Asp	Phe	Val	Ser	Lys	Thr	Val	Ile	Lys	Pro	Glu	Ser	
					290					295					300	
tgt	gtt	ccg	tgt	gga	aag	cgg	atc	aag	ttt	ggc	aag	ctg	tct	ctg	aag	1082
Cys	Val	Pro	Cys	Gly	Lys	Arg	Ile	Lys	Phe	Gly	Lys	Leu	Ser	Leu	Lys	
				305					310					315		
tgt	cga	gac	tgt	cgt	ttg	gtc	tcc	cat	cca	gaa	tgt	cgg	gac	cga	tgt	1130
Cys	Arg	Asp	Cys	Arg	Leu	Val	Ser	His	Pro	Glu	Cys	Arg	Asp	Arg	Cys	
				320				325					330			
ccc	ctt	ccc	tgc	atc	ccc	ccc	ctg	gtg	ggg	aca	ccg	gtt	aag	att	gga	1178
Pro	Leu	Pro	Cys	Ile	Pro	Pro	Leu	Val	Gly	Thr	Pro	Val	Lys	Ile	Gly	
			335				340					345				
gag	ggc	atg	ctg	gcc	gac	ttc	gtg	tgc	cag	gct	tct	ccc	atg	atc	cct	1226
Glu	Gly	Met	Leu	Ala	Asp	Phe	Val	Ser	Gln	Ala	Ser	Pro	Met	Ile	Pro	
		350				355					360					
gcc	att	gtc	gtc	agc	tgt	gtc	aat	gag	atc	gag	cag	cga	ggc	ctg	act	1274
Ala	Ile	Val	Val	Ser	Cys	Val	Asn	Glu	Ile	Glu	Gln	Arg	Gly	Leu	Thr	
					370					375					380	
gag	gca	ggc	ttg	tac	agg	atc	tca	ggc	tgt	gac	cgc	aca	gtg	aaa	gaa	1322
Glu	Ala	Gly	Leu	Tyr	Arg	Ile	Ser	Gly	Cys	Asp	Arg	Thr	Val	Lys	Glu	
				385					390					395		
ctg	aaa	gaa	aaa	ttc	ctt	aag	gtg	aaa	act	gtg	ccc	ctc	ctc	agc	aaa	1370
Leu	Lys	Glu	Lys	Phe	Leu	Lys	Val	Lys	Thr	Val	Pro	Leu	Leu	Ser	Lys	
			400					405					410			
gtg	gac	gat	atc	cac	gtc	atc	tgc	agc	ctc	ctg	aag	gac	ttc	ctg	cgc	1418
Val	Asp	Asp	Ile	His	Val	Ile	Cys	Ser	Leu	Leu	Lys	Asp	Phe	Leu	Arg	
			415				420					425				
aac	ctc	aaa	gag	ccc	ctc	ctg	acc	ttc	tgg	ctg	agc	aaa	gcc	ttc	atg	1466
Asn	Leu	Lys	Glu	Pro	Leu	Leu	Thr	Phe	Trp	Leu	Ser	Lys	Ala	Phe	Met	
			430			435					440					
gag	gca	gca	gag	ata	aca	gat	gaa	gac	aac	agc	aca	gcc	gcc	atg	tac	1514
Glu	Ala	Ala	Glu	Ile	Thr	Asp	Glu	Asp	Asn	Ser	Thr	Ala	Ala	Met	Tyr	
					450					455					460	
cag	gct	gtc	agt	gag	ctg	ccc	cag	gcc	aac	agg	gac	acg	cta	gcc	ttc	1562
Gln	Ala	Val	Ser	Glu	Leu	Pro	Gln	Ala	Asn	Arg	Asp	Thr	Leu	Ala	Phe	
				465					470					475		

ctt atg atc cac cta cag aga gtg tct cag agt cca gac act aag atg 1610
 Leu Met Ile His Leu Gln Arg Val Ser Gln Ser Pro Asp Thr Lys Met
 480 485 490

gat att gcc aat cta gct aaa gtc ttt ggc cct aca ata gtt gcc cat 1658
 Asp Ile Ala Asn Leu Ala Lys Val Phe Gly Pro Thr Ile Val Ala His
 495 500 505

act gtg ccc aat cca gat cca gtg aca atg ttc cag gac atc aaa cgt 1706
 Thr Val Pro Asn Pro Asp Pro Val Thr Met Phe Gln Asp Ile Lys Arg
 510 515 520

cag ctc aag gtg gtg gag cgc cta ctc tct ctc ccc ttg gag tac tgg 1754
 Gln Leu Lys Val Val Glu Arg Leu Leu Ser Leu Pro Leu Glu Tyr Trp
 525 530 535 540

aat cag ttc atg atg gtg gac caa gag aac ata gac agc cag cga ggc 1802
 Asn Gln Phe Met Met Val Asp Gln Glu Asn Ile Asp Ser Gln Arg Gly
 545 550 555

aat gga aac tca aca cca cgc aca cca gac gtt aaa gtg agc tta ctg 1850
 Asn Gly Asn Ser Thr Pro Arg Thr Pro Asp Val Lys Val Ser Leu Leu
 560 565 570

ggg cct gtg acc act cct gaa ttc cag ctt gtc aag act cct tta tca 1898
 Gly Pro Val Thr Thr Pro Glu Phe Gln Leu Val Lys Thr Pro Leu Ser
 575 580 585

agt tcc ctg tca cag agg ttg tac aac ctc tcc aag agc aca ccc aga 1946
 Ser Ser Leu Ser Gln Arg Leu Tyr Asn Leu Ser Lys Ser Thr Pro Arg
 590 595 600

ttt ggg aac aag agc aag tct gcc acc aac tta ggt caa cag ggc aaa 1994
 Phe Gly Asn Lys Ser Lys Ser Ala Thr Asn Leu Gly Gln Gln Gly Lys
 605 610 615 620

ttt ttc cct gct ccg tac ctc aag taa agctgtgtct gcctgtgttt 2041
 Phe Phe Pro Ala Pro Tyr Leu Lys
 625

actgcacgag acacccctgt ctgctcttca gcctcctgtg taatgactac ttttagcatt 2101

ttccagactt taaataaagt tgaacgcgta tgagagtttg agtggtgcat agctccctcc 2161

cacctggaca cttagcacct ttactagttg tcgggagctt taaaatagga gatctttacc 2221

agggccgaag gggaaatggg tataagttgg ggctcttagg gggaggggag aggagatccc 2281

tttggcttaa agccaaatac tgctcatgaa atgactttgc tgtggtgtca cttagacaat 2341

gacagaaact gtaccttta ggtaacgtct tagttatctc aggacaggat aaagagctgc 2401

gcagcgcccc cttctcagaa cacaggcctc ttctctcttc ggggactgac aagaagcttg 2461

gagccctcag cgggatgggc cgggccactg atctgaggat gcttcacttc tgtctggggt 2521

aagctgagaa agtgccacag gctctgatct cacacagcgt gctgtttcta gccagcctct 2581

11

gcctggattt tgcagtcaaa gtcaggttga tctgaagccg aattcgttct gatgcctgac 2641
 ccccttggtt gtccagtggg gcccatTTaa aaagtcagct agcagttcag aagacaattt 2701
 tcatatagca agaaagttag ctgcttctgt ctttggtgaa gtttttctgt gaaacagatc 2761
 tatatatgtg aacattggct tttttggtta gcattttcca gtgttcaaaa tggcttctt 2821
 ccctgggatg ttttctgacc catactaacc cttacctgta acatgtatct ggaatattat 2881
 gtggaaaaaa taaatagctt tttcaaagtg aactttcc 2919

<210> 4
 <211> 628
 <212> PRT
 <213> Mus musculus

<400> 4

Met	Asp	Thr	Thr	Met	Val	Asn	Leu	Trp	Thr	Leu	Phe	Glu	Gln	Leu	Val
1				5					10					15	
Arg	Arg	Met	Glu	Ile	Ile	Asn	Glu	Gly	Asn	Glu	Ser	Ile	Glu	Phe	Ile
			20					25					30		
Gln	Val	Val	Lys	Asp	Phe	Glu	Asp	Phe	Arg	Lys	Lys	Tyr	Gln	Arg	Thr
		35					40					45			
Asn	Gln	Glu	Leu	Glu	Lys	Phe	Lys	Asp	Leu	Leu	Leu	Lys	Ala	Glu	Thr
	50					55					60				
Gly	Arg	Ser	Ala	Leu	Asp	Val	Lys	Leu	Lys	His	Ala	Arg	Asn	Gln	Val
65					70					75				80	
Asp	Val	Glu	Ile	Lys	Arg	Arg	Gln	Arg	Ala	Glu	Ala	Glu	Cys	Ala	Lys
				85					90					95	
Leu	Glu	Gln	Gln	Ile	Gln	Leu	Ile	Arg	Asp	Ile	Leu	Met	Cys	Asp	Thr
			100					105					110		
Ser	Gly	Ser	Ile	Gln	Leu	Ser	Glu	Glu	Gln	Lys	Ser	Ala	Leu	Ala	Phe
		115					120					125			
Leu	Asn	Arg	Gly	Gln	Ala	Ser	Ser	Gly	His	Ala	Gly	Asn	Asn	Arg	Leu
	130					135					140				
Ser	Thr	Ile	Asp	Glu	Ser	Gly	Ser	Ile	Leu	Ser	Asp	Ile	Ser	Phe	Asp
145					150					155				160	
Lys	Thr	Asp	Glu	Ser	Leu	Asp	Trp	Asp	Ser	Ser	Leu	Val	Lys	Asn	Phe
				165					170					175	
Lys	Met	Lys	Lys	Arg	Glu	Lys	Arg	Arg	Ser	Asn	Ser	Arg	Gln	Phe	Ile
			180					185					190		

12

```

Asp Gly Pro Pro Gly Pro Val Lys Lys Thr Cys Ser Ile Gly Ser Thr
195                200                205

Val Asp Gln Ala Asn Glu Ser Ile Val Ala Lys Thr Thr Val Thr Val
210                215                220

Pro Ser Asp Gly Gly Pro Ile Glu Ala Val Ser Thr Ile Glu Thr Leu
225                230                235                240

Pro Ser Trp Thr Arg Ser Arg Gly Lys Ser Gly Pro Leu Gln Pro Val
245                250                255

Asn Ser Asp Ser Ala Leu Asn Ser Arg Pro Leu Glu Pro Arg Thr Asp
260                265                270

Thr Asp Asn Leu Gly Thr Pro Gln Asn Thr Gly Gly Met Arg Leu His
275                280                285

Asp Phe Val Ser Lys Thr Val Ile Lys Pro Glu Ser Cys Val Pro Cys
290                295                300

Gly Lys Arg Ile Lys Phe Gly Lys Leu Ser Leu Lys Cys Arg Asp Cys
305                310                315                320

Arg Leu Val Ser His Pro Glu Cys Arg Asp Arg Cys Pro Leu Pro Cys
325                330                335

Ile Pro Pro Leu Val Gly Thr Pro Val Lys Ile Gly Glu Gly Met Leu
340                345                350

Ala Asp Phe Val Ser Gln Ala Ser Pro Met Ile Pro Ala Ile Val Val
355                360                365

Ser Cys Val Asn Glu Ile Glu Gln Arg Gly Leu Thr Glu Ala Gly Leu
370                375                380

Tyr Arg Ile Ser Gly Cys Asp Arg Thr Val Lys Glu Leu Lys Glu Lys
385                390                395                400

Phe Leu Lys Val Lys Thr Val Pro Leu Leu Ser Lys Val Asp Asp Ile
405                410                415

His Val Ile Cys Ser Leu Leu Lys Asp Phe Leu Arg Asn Leu Lys Glu
420                425                430

Pro Leu Leu Thr Phe Trp Leu Ser Lys Ala Phe Met Glu Ala Ala Glu
435                440                445

Ile Thr Asp Glu Asp Asn Ser Thr Ala Ala Met Tyr Gln Ala Val Ser
450                455                460

Glu Leu Pro Gln Ala Asn Arg Asp Thr Leu Ala Phe Leu Met Ile His
465                470                475                480

Leu Gln Arg Val Ser Gln Ser Pro Asp Thr Lys Met Asp Ile Ala Asn
485                490                495

```

13

Leu Ala Lys Val Phe Gly Pro Thr Ile Val Ala His Thr Val Pro Asn
 500 505 510
 Pro Asp Pro Val Thr Met Phe Gln Asp Ile Lys Arg Gln Leu Lys Val
 515 520 525
 Val Glu Arg Leu Leu Ser Leu Pro Leu Glu Tyr Trp Asn Gln Phe Met
 530 535 540
 Met Val Asp Gln Glu Asn Ile Asp Ser Gln Arg Gly Asn Gly Asn Ser
 545 550 555 560
 Thr Pro Arg Thr Pro Asp Val Lys Val Ser Leu Leu Gly Pro Val Thr
 565 570 575
 Thr Pro Glu Phe Gln Leu Val Lys Thr Pro Leu Ser Ser Ser Leu Ser
 580 585 590
 Gln Arg Leu Tyr Asn Leu Ser Lys Ser Thr Pro Arg Phe Gly Asn Lys
 595 600 605
 Ser Lys Ser Ala Thr Asn Leu Gly Gln Gln Gly Lys Phe Phe Pro Ala
 610 615 620
 Pro Tyr Leu Lys
 625

<210> 5
 <211> 2046
 <212> DNA
 <213> Caenorhabditis elegans

<220>
 <221> CDS
 <222> (1)..(2046)

<400> 5

atg aag tcc agt aca tca aaa gag aag gtg tgc ggc gaa aac tcg cgt	48
Met Lys Ser Ser Thr Ser Lys Glu Lys Val Cys Gly Glu Asn Ser Arg	
1 5 10 15	
cac att ttc aac atg att cta aac tca cag cga ccg caa ttc gat att	96
His Ile Phe Asn Met Ile Leu Asn Ser Gln Arg Pro Gln Phe Asp Ile	
20 25 30	
aag gat ata gga atg ttt cat ttg att gat gag att gag cgt ctc cgc	144
Lys Asp Ile Gly Met Phe His Leu Ile Asp Glu Ile Glu Arg Leu Arg	
35 40 45	
aag ctg tgg aaa gat tcc gag gaa tcc aaa aag cgg ctg aat gca gat	192
Lys Leu Trp Lys Asp Ser Glu Glu Ser Lys Lys Arg Leu Asn Ala Asp	
50 55 60	

14

atg	aga	gag	gcc	gaa	gaa	gca	ctt	gca	aaa	gct	cgc	aag	aag	ctg	gca	240
Met	Arg	Glu	Ala	Glu	Glu	Ala	Leu	Ala	Lys	Ala	Arg	Lys	Lys	Leu	Ala	
65					70				75						80	
atg	ttc	gat	atc	gat	gtc	aaa	gac	act	cag	aaa	cat	tta	cgc	gcg	ttg	288
Met	Phe	Asp	Ile	Asp	Val	Lys	Asp	Thr	Gln	Lys	His	Leu	Arg	Ala	Leu	
				85					90						95	
atg	gaa	gaa	aat	aag	gcg	ttg	aag	ctc	gat	cta	aac	gtc	tac	gag	act	336
Met	Glu	Glu	Asn	Lys	Ala	Leu	Lys	Leu	Asp	Leu	Asn	Val	Tyr	Glu	Thr	
			100					105						110		
cgt	gaa	aag	cag	ctg	aaa	gat	gcg	atg	aag	aac	ggt	ata	ttc	aat	agt	384
Arg	Glu	Lys	Gln	Leu	Lys	Asp	Ala	Met	Lys	Asn	Gly	Ile	Phe	Asn	Ser	
		115					120					125				
ctc	acc	aag	gaa	gac	cgc	gat	cag	ttc	aag	ttt	ctt	cac	gag	cca	ctg	432
Leu	Thr	Lys	Glu	Asp	Arg	Asp	Gln	Phe	Lys	Phe	Leu	His	Glu	Pro	Leu	
		130				135					140					
gtc	cgg	aca	tac	tcg	aaa	cgg	gtg	cag	cag	agg	cat	cca	cat	ttg	atg	480
Val	Arg	Thr	Tyr	Ser	Lys	Arg	Val	Gln	Gln	Arg	His	Pro	His	Leu	Met	
145					150					155					160	
gag	gac	aca	cag	gac	gat	gag	gac	gat	agt	gag	gtg	gat	tac	gat	gaa	528
Glu	Asp	Thr	Gln	Asp	Asp	Glu	Asp	Asp	Ser	Glu	Val	Asp	Tyr	Asp	Glu	
				165					170					175		
act	gga	gac	agt	ttc	gag	gaa	gtt	att	cat	ttg	cgc	aat	gga	aga	gag	576
Thr	Gly	Asp	Ser	Phe	Glu	Glu	Val	Ile	His	Leu	Arg	Asn	Gly	Arg	Glu	
			180					185					190			
gtc	aga	aga	agc	tca	gct	gct	gga	aac	gca	gtt	ggt	ggc	aag	cgg	aga	624
Val	Arg	Arg	Ser	Ser	Ala	Ala	Gly	Asn	Ala	Val	Gly	Gly	Lys	Arg	Arg	
			195				200					205				
agc	gcg	tca	gca	cat	gcg	att	act	gct	gct	gcc	aat	tcg	aag	agg	agc	672
Ser	Ala	Ser	Ala	His	Ala	Ile	Thr	Ala	Ala	Ala	Asn	Ser	Lys	Arg	Ser	
			210			215					220					
aga	agc	cgt	gtt	atg	aca	gct	act	ata	gat	gaa	gag	ccg	aat	gag	ggt	720
Arg	Ser	Arg	Val	Met	Thr	Ala	Thr	Ile	Asp	Glu	Glu	Pro	Asn	Glu	Gly	
225					230					235					240	
ggt	aca	cct	cca	aaa	aga	tgc	cgt	gat	gat	ggt	tct	aca	cct	cat	caa	768
Gly	Thr	Pro	Pro	Lys	Arg	Cys	Arg	Asp	Asp	Gly	Ser	Thr	Pro	His	Gln	
				245					250					255		
gaa	atg	aca	act	acc	acc	act	acc	acc	acc	acc	act	act	att	cat	aac	816
Glu	Met	Thr	Thr	Thr	Thr	Thr	Thr	Thr	Thr	Thr	Thr	Thr	Ile	His	Asn	
			260					265					270			
tct	cga	gct	cag	aac	cag	gac	ccg	cca	cgt	gtc	tca	ctt	cac	cgc	cag	864
Ser	Arg	Ala	Gln	Asn	Gln	Asp	Pro	Pro	Arg	Val	Ser	Leu	His	Arg	Gln	
			275				280					285				

15

ctc acc cgc agg agc ttg agc tgt gga agt att cca tca tgc gat caa	912
Leu Thr Arg Arg Ser Leu Ser Cys Gly Ser Ile Pro Ser Cys Asp Gln	
290 295 300	
aca cca gga caa acc aca aat aac atc ggc ctc ggc atg tcg tcc gcc	960
Thr Pro Gly Gln Thr Thr Asn Asn Ile Gly Leu Gly Met Ser Ser Ala	
305 310 315 320	
att ctc acc aaa agc aca ctt gat atc cga acc ctg aaa cgt ggc acg	1008
Ile Leu Thr Lys Ser Thr Leu Asp Ile Arg Thr Leu Lys Arg Gly Thr	
325 330 335	
ccg gcg tgg act aat gga aca act cgt gac atc gca atg aga cca cac	1056
Pro Ala Trp Thr Asn Gly Thr Thr Arg Asp Ile Ala Met Arg Pro His	
340 345 350	
acg ttt ata gag gca gga atc aaa gcg atg cga aaa tgc gac aaa tgt	1104
Thr Phe Ile Glu Ala Gly Ile Lys Ala Met Arg Lys Cys Asp Lys Cys	
355 360 365	
gct aca gcc ctg aag ctc gcc aca tca atg aaa tgc aga gac tgt cac	1152
Ala Thr Ala Leu Lys Leu Ala Thr Ser Met Lys Cys Arg Asp Cys His	
370 375 380	
cag gtt gtc cat cgt agt tgc tgc aac aaa ctt cat ctc ccg tgc ata	1200
Gln Val Val His Arg Ser Cys Cys Asn Lys Leu His Leu Pro Cys Ile	
385 390 395 400	
cca cgc ccc aag acg atg atg acg ccg aaa tcc gca tta cgt gga gcc	1248
Pro Arg Pro Lys Thr Met Met Thr Pro Lys Ser Ala Leu Arg Gly Ala	
405 410 415	
aag ccg ggc gca gga gag ttc cga ctt caa gat ttg tgc aca tct gcg	1296
Lys Pro Gly Ala Gly Glu Phe Arg Leu Gln Asp Leu Cys Thr Ser Ala	
420 425 430	
aag cca atg atc ccg gca gca gtt att cat tgt gtg gtt gcc ctg gag	1344
Lys Pro Met Ile Pro Ala Ala Val Ile His Cys Val Val Ala Leu Glu	
435 440 445	
gct cgt gga ctc acg cag gaa ggt att tac cgc gtt cct ggg cag gtt	1392
Ala Arg Gly Leu Thr Gln Glu Gly Ile Tyr Arg Val Pro Gly Gln Val	
450 455 460	
aga act gtc aat gtg ctt ttg gac gag ttg aga tca aaa acg gta ccc	1440
Arg Thr Val Asn Val Leu Leu Asp Glu Leu Arg Ser Lys Thr Val Pro	
465 470 475 480	
aac gtg ggc ctt cac gac gtt gag gtc atc aca gac acc ttg aaa ccg	1488
Asn Val Gly Leu His Asp Val Glu Val Ile Thr Asp Thr Leu Lys Arg	
485 490 495	
ttc cta aga gat ctt aaa gac ccg ttg atc cca aga acg tct cgt caa	1536
Phe Leu Arg Asp Leu Lys Asp Pro Leu Ile Pro Arg Thr Ser Arg Gln	
500 505 510	

gag ctc atc gtt gct gca aac ctc tac tct acg gat cca gat aat gga 1584
 Glu Leu Ile Val Ala Ala Asn Leu Tyr Ser Thr Asp Pro Asp Asn Gly
 515 520 525

cgt ctc gcc ctg aat cga gtg atc tgt gag ctc ccc caa gcg aat cga 1632
 Arg Leu Ala Leu Asn Arg Val Ile Cys Glu Leu Pro Gln Ala Asn Arg
 530 535 540

gac acc ctc gcc tac ctt ttc att cac tgg cgc aaa gtt atc gca caa 1680
 Asp Thr Leu Ala Tyr Leu Phe Ile His Trp Arg Lys Val Ile Ala Gln
 545 550 555 560

tcg agt cgc aac aag atg aac tgc gaa gcg atg gcg cgg atg gtg gct 1728
 Ser Ser Arg Asn Lys Met Asn Cys Glu Ala Met Ala Arg Met Val Ala
 565 570 575

ccg gcg gtg atg ggt cat cca gtg aag caa tcg cag tcc caa gcg ata 1776
 Pro Ala Val Met Gly His Pro Val Lys Gln Ser Gln Ser Gln Ala Ile
 580 585 590

gct ggc aga gat gcc acg gat tgc cat cga gcg atg act gct cta ttt 1824
 Ala Gly Arg Asp Ala Thr Asp Cys His Arg Ala Met Thr Ala Leu Phe
 595 600 605

gaa ttt gat gat gta tat tgg caa cga ttc cta ggg aca tct gca gtt 1872
 Glu Phe Asp Asp Val Tyr Trp Gln Arg Phe Leu Gly Thr Ser Ala Val
 610 615 620

tcc atg gct tct aat caa att gaa acg gct cga cat cag gac aat ttt 1920
 Ser Met Ala Ser Asn Gln Ile Glu Thr Ala Arg His Gln Asp Asn Phe
 625 630 635 640

gct ctc tgt gat cgt agc atc ctt gga cca gtt aca aca tca cca gcc 1968
 Ala Leu Cys Asp Arg Ser Ile Leu Gly Pro Val Thr Thr Ser Pro Ala
 645 650 655

act ccc ctg ctt gct cgg tcg gcc aac gcg act cga gca cgt ggt gct 2016
 Thr Pro Leu Leu Ala Arg Ser Ala Asn Ala Thr Arg Ala Arg Gly Ala
 660 665 670

cat ctg ctg ggg tcg atg ttc cac gat tag 2046
 His Leu Leu Gly Ser Met Phe His Asp
 675 680

<210> 6
 <211> 681
 <212> PRT
 <213> Caenorhabditis elegans

<400> 6

Met Lys Ser Ser Thr Ser Lys Glu Lys Val Cys Gly Glu Asn Ser Arg
 1 5 10 15

His Ile Phe Asn Met Ile Leu Asn Ser Gln Arg Pro Gln Phe Asp Ile
 20 25 30

Lys Asp Ile Gly Met Phe His Leu Ile Asp Glu Ile Glu Arg Leu Arg
 35 40 45
 Lys Leu Trp Lys Asp Ser Glu Glu Ser Lys Lys Arg Leu Asn Ala Asp
 50 55 60
 Met Arg Glu Ala Glu Glu Ala Leu Ala Lys Ala Arg Lys Lys Leu Ala
 65 70 75 80
 Met Phe Asp Ile Asp Val Lys Asp Thr Gln Lys His Leu Arg Ala Leu
 85 90 95
 Met Glu Glu Asn Lys Ala Leu Lys Leu Asp Leu Asn Val Tyr Glu Thr
 100 105 110
 Arg Glu Lys Gln Leu Lys Asp Ala Met Lys Asn Gly Ile Phe Asn Ser
 115 120 125
 Leu Thr Lys Glu Asp Arg Asp Gln Phe Lys Phe Leu His Glu Pro Leu
 130 135 140
 Val Arg Thr Tyr Ser Lys Arg Val Gln Gln Arg His Pro His Leu Met
 145 150 155 160
 Glu Asp Thr Gln Asp Asp Glu Asp Asp Ser Glu Val Asp Tyr Asp Glu
 165 170 175
 Thr Gly Asp Ser Phe Glu Glu Val Ile His Leu Arg Asn Gly Arg Glu
 180 185 190
 Val Arg Arg Ser Ser Ala Ala Gly Asn Ala Val Gly Gly Lys Arg Arg
 195 200 205
 Ser Ala Ser Ala His Ala Ile Thr Ala Ala Ala Asn Ser Lys Arg Ser
 210 215 220
 Arg Ser Arg Val Met Thr Ala Thr Ile Asp Glu Glu Pro Asn Glu Gly
 225 230 235 240
 Gly Thr Pro Pro Lys Arg Cys Arg Asp Asp Gly Ser Thr Pro His Gln
 245 250 255
 Glu Met Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Ile His Asn
 260 265 270
 Ser Arg Ala Gln Asn Gln Asp Pro Pro Arg Val Ser Leu His Arg Gln
 275 280 285
 Leu Thr Arg Arg Ser Leu Ser Cys Gly Ser Ile Pro Ser Cys Asp Gln
 290 295 300
 Thr Pro Gly Gln Thr Thr Asn Asn Ile Gly Leu Gly Met Ser Ser Ala
 305 310 315 320
 Ile Leu Thr Lys Ser Thr Leu Asp Ile Arg Thr Leu Lys Arg Gly Thr
 325 330 335

18

Pro Ala Trp Thr Asn Gly Thr Thr Arg Asp Ile Ala Met Arg Pro His
 340 345 350
 Thr Phe Ile Glu Ala Gly Ile Lys Ala Met Arg Lys Cys Asp Lys Cys
 355 360 365
 Ala Thr Ala Leu Lys Leu Ala Thr Ser Met Lys Cys Arg Asp Cys His
 370 375 380
 Gln Val Val His Arg Ser Cys Cys Asn Lys Leu His Leu Pro Cys Ile
 385 390 395 400
 Pro Arg Pro Lys Thr Met Met Thr Pro Lys Ser Ala Leu Arg Gly Ala
 405 410 415
 Lys Pro Gly Ala Gly Glu Phe Arg Leu Gln Asp Leu Cys Thr Ser Ala
 420 425 430
 Lys Pro Met Ile Pro Ala Ala Val Ile His Cys Val Val Ala Leu Glu
 435 440 445
 Ala Arg Gly Leu Thr Gln Glu Gly Ile Tyr Arg Val Pro Gly Gln Val
 450 455 460
 Arg Thr Val Asn Val Leu Leu Asp Glu Leu Arg Ser Lys Thr Val Pro
 465 470 475 480
 Asn Val Gly Leu His Asp Val Glu Val Ile Thr Asp Thr Leu Lys Arg
 485 490 495
 Phe Leu Arg Asp Leu Lys Asp Pro Leu Ile Pro Arg Thr Ser Arg Gln
 500 505 510
 Glu Leu Ile Val Ala Ala Asn Leu Tyr Ser Thr Asp Pro Asp Asn Gly
 515 520 525
 Arg Leu Ala Leu Asn Arg Val Ile Cys Glu Leu Pro Gln Ala Asn Arg
 530 535 540
 Asp Thr Leu Ala Tyr Leu Phe Ile His Trp Arg Lys Val Ile Ala Gln
 545 550 555 560
 Ser Ser Arg Asn Lys Met Asn Cys Glu Ala Met Ala Arg Met Val Ala
 565 570 575
 Pro Ala Val Met Gly His Pro Val Lys Gln Ser Gln Ser Gln Ala Ile
 580 585 590
 Ala Gly Arg Asp Ala Thr Asp Cys His Arg Ala Met Thr Ala Leu Phe
 595 600 605
 Glu Phe Asp Asp Val Tyr Trp Gln Arg Phe Leu Gly Thr Ser Ala Val
 610 615 620
 Ser Met Ala Ser Asn Gln Ile Glu Thr Ala Arg His Gln Asp Asn Phe
 625 630 635 640

19

Ala Leu Cys Asp Arg Ser Ile Leu Gly Pro Val Thr Thr Ser Pro Ala
645 650 655

Thr Pro Leu Leu Ala Arg Ser Ala Asn Ala Thr Arg Ala Arg Gly Ala
660 665 670

His Leu Leu Gly Ser Met Phe His Asp
675 680

63

EPO - Munich
31

19. Juni 2000

Claims

1. Human polypeptide designated Cyk-4, which is a
GTPase activating protein (GAP) for Rho family of
5 GTPases, with the amino acid sequence as set forth
in SEQ ID NO:2 or with the amino acid sequence
encoded by a polynucleotide which hybridizes under
stringent conditions to a polynucleotide having a
nucleotide sequence as set forth in SEQ ID NO:1.
- 10
2. Murine Cyk-4 polypeptide designated Cyk-4, which is
a GTPase activating protein (GAP) for Rho family of
GTPases, with the amino acid sequence as set forth,
15 in SEQ ID NO:4 or with the amino acid sequence
encoded by a polynucleotide which hybridizes under
stringent conditions to a polynucleotide having a
nucleotide sequence as set forth in SEQ ID NO:3.
- 20
3. An isolated DNA molecule comprising a
polynucleotide with the nucleotide sequence as set
forth in SEQ ID NO:1 encoding human Cyk-4
polypeptide, or an isolated DNA molecule encoding
human Cyk-4 polypeptide comprising a polynucleotide
which hybridizes under stringent conditions to a
25 polynucleotide having a nucleotide sequence as set
forth in SEQ ID NO:1.

4. An isolated DNA molecule comprising a polynucleotide with the nucleotide sequence as set forth in SEQ ID NO:3 encoding murine Cyk-4 polypeptide, or an isolated DNA molecule encoding murine Cyk-4 polypeptide comprising a polynucleotide which hybridizes under stringent conditions to a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO:3.
5. An antibody which is specifically reactive with an epitope of the human Cyk-4 polypeptide of claim 1.
6. An antibody which is specifically reactive with an epitope of the murine Cyk-4 polypeptide of claim 2.
7. A method for identifying a compound capable of modulating cytokinesis, wherein the compound's ability to modulate the function of CYK- is determined.
8. The method of claim 7 wherein the compound's ability to promote GTP hydrolysis by a Rho family GTPase is determined by incubating a substrate selected from the members of the Rho family GTPases with GTP for a period of time sufficient to allow saturation of the substrate's GTP binding sites, adding Cyk-4 and allowing it to react in the presence or absence of the test compound, and determining the amount of hydrolyzed GTP.

9. The method of claim 7 wherein the compound's ability to inhibit Cyk-4 function is determined by determining the compound's ability to interfere with the biochemical interaction of CYK-4 and a member of the MKLP1 subfamily.
- 5
10. A compound identified in the method of any one of claims 7 to 9 for use in cancer therapy.

EPO - Munich
31

19. Juni 2000

Abstract

5 Mammalian CYK-4 polypeptides, which are key molecules
required for cytokinesis, and DNA molecules encoding
them. Screening methods based on the function of CYK-4
to promote GTP hydrolysis by Rho family GTPases can be
employed to identify compounds interfering with cell
10 division. Such compounds are useful in tumour therapy.

Fig. 1
EPO - Munich
31
19. Juni 2000




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10

